Philip Kantoff

Q: What Schools Are Affiliated With Philip Kantoff

Philip Kantoff is affiliated with the following schools: University of Michigan, Icahn School of Medicine at Mount Sinai, University of California, Los Angeles, Gwangju Institute of Science and Technology, University of Chicago, Columbia University, Massachusetts General Hospital, Duke University, Brown University, Worcester Polytechnic Institute, University of British Columbia, Medical University of South Carolina, Georgetown University, University of Colorado, Johns Hopkins University, University of Connecticut, Harvard University, University of Pennsylvania

Philip Kantoff's AcademicInfluence.com Rankings

Philip Kantoff

Biology

#3168

World Rank

#4885

Historical Rank

Immunology

#214

World Rank

#223

Historical Rank

biology Degrees

Philip Kantoff

Philosophy

#3759

World Rank

#6022

Historical Rank

Logic

#1456

World Rank

#2212

Historical Rank

philosophy Degrees

Download Badge

Biology
Philosophy

Philip Kantoff's Degrees

Doctorate Medicine University of Pennsylvania
PhD Immunology University of Pennsylvania

Why Is Philip Kantoff Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Philip W. Kantoff is a medical oncologist. He is the chairman and chief executive officer of Convergent Therapeutics. He served as the Chairman of Medicine at Memorial Sloan Kettering Cancer Center between 2015 and 2021. He is best known for his contributions to the impact of DNA abnormalities in prostate cancer and the discovery of therapies for metastatic hormone-sensitive prostate cancer.

(See a Problem?)

Philip Kantoff's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Sipuleucel-T immunotherapy for castration-resistant prostate cancer. (2010) (4808)
Cancer nanomedicine: progress, challenges and opportunities (2016) (3400)
Gene expression correlates of clinical prostate cancer behavior. (2002) (2549)
Integrative Clinical Genomics of Advanced Prostate Cancer (2015) (2458)
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. (2008) (2023)
Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. (2006) (1580)
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer (2012) (1367)
The genomic complexity of primary human prostate cancer (2010) (1195)
Punctuated Evolution of Prostate Cancer Genomes (2013) (1105)
Early detection of prostate cancer: AUA Guideline. (2013) (1061)
Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. (2016) (1060)
Preclinical Development and Clinical Translation of a PSMA-Targeted Docetaxel Nanoparticle with a Differentiated Pharmacological Profile (2012) (1001)
NCCN clinical practice guidelines in oncology: prostate cancer. (2010) (971)
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. (2015) (934)
Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. (1999) (902)
Androgen Receptor Regulates a Distinct Transcription Program in Androgen-Independent Prostate Cancer (2009) (891)
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. (2016) (889)
The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. (1997) (888)
Quantum dot-aptamer conjugates for synchronous cancer imaging, therapy, and sensing of drug delivery based on bi-fluorescence resonance energy transfer. (2007) (878)
Prostate cancer. Clinical practice guidelines in oncology. (2007) (839)
Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. (2010) (836)
EZH2 Oncogenic Activity in Castration-Resistant Prostate Cancer Cells Is Polycomb-Independent (2012) (724)
Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. (2001) (703)
Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. (2008) (684)
Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. (2003) (675)
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. (2004) (649)
Changes in body composition during androgen deprivation therapy for prostate cancer. (2002) (649)
Genomic correlates of clinical outcome in advanced prostate cancer (2019) (647)
Autoantibody signatures in prostate cancer. (2005) (606)
Adverse effects of androgen deprivation therapy and strategies to mitigate them. (2015) (562)
Self-inactivating retroviral vectors designed for transfer of whole genes into mammalian cells. (1986) (535)
The long tail of oncogenic drivers in prostate cancer (2018) (529)
TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort (2007) (506)
Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. (2007) (498)
Whole exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer (2014) (479)
Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer. (2000) (458)
Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. (2018) (452)
Contemporary trends in low risk prostate cancer: risk assessment and treatment. (2007) (448)
Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. (2014) (445)
Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. (2012) (431)
Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. (2003) (398)
Her-2-neu expression and progression toward androgen independence in human prostate cancer. (2000) (392)
Integrative Clinical Genomics of Advanced Prostate Cancer (2015) (383)
Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. (2010) (382)
Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade (2019) (364)
Prostate cancer, Version 3.2012: featured updates to the NCCN guidelines. (2012) (358)
Whole-exome sequencing and clinical interpretation of formalin-fixed , paraffin-embedded tumor samples to guide precision cancer medicine (2014) (339)
Effect of internal viral sequences on the utility of retroviral vectors (1987) (325)
Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. (2007) (325)
Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. (2008) (322)
Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing (2017) (321)
Patient-reported symptoms after primary therapy for early prostate cancer: results of a prospective cohort study. (1998) (321)
TMPRSS2 and COVID-19: Serendipity or opportunity for intervention? (2020) (318)
A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. (2000) (316)
Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making. (2017) (309)
Enhancer RNAs participate in androgen receptor-driven looping that selectively enhances gene activation (2014) (307)
Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology. (2019) (306)
Institutional implementation of clinical tumor profiling on an unselected cancer population. (2016) (303)
The androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesis (2015) (296)
Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: The MPAKT model (2003) (292)
The TMPRSS2:ERG Rearrangement, ERG Expression, and Prostate Cancer Outcomes: A Cohort Study and Meta-analysis (2012) (291)
Enhancing tumor cell response to chemotherapy through nanoparticle-mediated codelivery of siRNA and cisplatin prodrug (2013) (285)
Superparamagnetic Iron Oxide Nanoparticle–Aptamer Bioconjugates for Combined Prostate Cancer Imaging and Therapy (2008) (279)
Prostate Cancer,,Version 2.2014 Clinical Practice Guidelines in Oncology (2014) (277)
Whole-exome sequencing and clinical interpretation of FFPE tumor samples to guide precision cancer medicine (2013) (275)
Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. (2001) (272)
The role of microRNA-221 and microRNA-222 in androgen-independent prostate cancer cell lines. (2009) (271)
Management of hormone refractory prostate cancer: current standards and future prospects. (1998) (267)
Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer. (2017) (262)
Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. (2014) (262)
Racial variation in prostate cancer incidence and in hormonal system markers among male health professionals. (2000) (261)
Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. (2020) (260)
Modification of BRCA1-associated breast cancer risk by the polymorphic androgen-receptor CAG repeat. (1999) (259)
Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer. (1999) (257)
Integrative analyses reveal a long noncoding RNA-mediated sponge regulatory network in prostate cancer (2016) (254)
Prostate cancer, version 2.2014. (2014) (252)
Gene expression in mice after high efficiency retroviral-mediated gene transfer. (1985) (250)
Functional Enhancers at the Gene-Poor 8q24 Cancer-Linked Locus (2009) (248)
Expression differences of circulating microRNAs in metastatic castration resistant prostate cancer and low‐risk, localized prostate cancer (2013) (237)
Manganese superoxide dismutase polymorphism, prediagnostic antioxidant status, and risk of clinical significant prostate cancer. (2005) (236)
Time course and predictors of symptoms after primary prostate cancer therapy. (2003) (234)
Sex Steroid Hormones and the Androgen Receptor Gene CAG Repeat and Subsequent Risk of Prostate Cancer in the Prostate-Specific Antigen Era (2005) (233)
Treatment of Advanced Prostate Cancer. (2019) (232)
Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer (2012) (231)
Molecular sampling of prostate cancer: a dilemma for predicting disease progression (2010) (227)
Active surveillance for early‐stage prostate cancer (2008) (227)
Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial. (2013) (224)
Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates. (2014) (222)
Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study. (2014) (213)
Patient-reported impotence and incontinence after nerve-sparing radical prostatectomy. (1997) (208)
Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis. (2010) (206)
The association between germline BRCA2 variants and sensitivity to platinum‐based chemotherapy among men with metastatic prostate cancer (2017) (203)
Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. (2004) (201)
Evidence that the CAG repeat in the androgen receptor gene is associated with the age-related decline in serum androgen levels in men. (1999) (198)
Complications after treatment with external-beam irradiation in early-stage prostate cancer patients: a prospective multiinstitutional outcomes study. (1997) (194)
Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer. (2001) (183)
Pain predicts overall survival in men with metastatic castration-refractory prostate cancer. (2008) (179)
Neoadjuvant Docetaxel before Radical Prostatectomy in Patients with High-Risk Localized Prostate Cancer (2005) (178)
Stable integration and expression of a bacterial gene in the mosquito Anopheles gambiae. (1987) (178)
Expression of human adenosine deaminase in nonhuman primates after retrovirus-mediated gene transfer (1987) (173)
Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer. (2012) (171)
Detection of circulating tumor cells in men with localized prostate cancer. (1994) (164)
Chemotherapy for teratoma with malignant transformation. (2003) (164)
The Prognostic Significance of Plasma Interleukin-6 Levels in Patients with Metastatic Hormone-Refractory Prostate Cancer: Results from Cancer and Leukemia Group B 9480 (2005) (163)
Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017. (2017) (160)
Biochemical outcome following external beam radiation therapy with or without androgen suppression therapy for clinically localized prostate cancer. (2000) (158)
Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study. (2001) (156)
Low bone mineral density in hormone‐naïve men with prostate carcinoma (2001) (156)
Correction of adenosine deaminase deficiency in cultured human T and B cells by retrovirus-mediated gene transfer. (1986) (155)
A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): Survival results of CALGB 90401. (2010) (155)
SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer. (2011) (154)
p63 regulates commitment to the prostate cell lineage. (2005) (153)
Restoration of tumour-growth suppression in vivo via systemic nanoparticle-mediated delivery of PTEN mRNA (2018) (152)
Screening for prostate cancer with prostate-specific antigen testing: American Society of Clinical Oncology Provisional Clinical Opinion. (2012) (151)
mRNA expression signature of Gleason grade predicts lethal prostate cancer. (2011) (150)
Abiraterone Treatment in Castration-Resistant Prostate Cancer Selects for Progesterone Responsive Mutant Androgen Receptors (2014) (150)
Current treatment strategies for advanced prostate cancer (2018) (148)
Development and Clinical Validation of an In Situ Biopsy-Based Multimarker Assay for Risk Stratification in Prostate Cancer (2015) (146)
Phase II study of sunitinib in men with advanced prostate cancer. (2009) (145)
Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy. (2006) (139)
MiR-221 promotes the development of androgen independence in prostate cancer cells via downregulation of HECTD2 and RAB1A (2014) (139)
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. (2015) (139)
Genome-wide loss of heterozygosity analysis from laser capture microdissected prostate cancer using single nucleotide polymorphic allele (SNP) arrays and a novel bioinformatics platform dChipSNP. (2003) (138)
A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel (2015) (138)
Modification of BRCA1- and BRCA2-associated breast cancer risk by AIB1 genotype and reproductive history. (2001) (137)
High-level recombinant gene expression in rabbit endothelial cells transduced by retroviral vectors. (1989) (131)
Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer (2019) (131)
Decreased α-Methylacyl CoA Racemase Expression in Localized Prostate Cancer is Associated with an Increased Rate of Biochemical Recurrence and Cancer-Specific Death (2005) (131)
Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate‐specific antigen level after radical prostatectomy and/or radiation therapy (2004) (130)
Diagnosis and Staging of Prostate Cancer (2003) (130)
Statin Use at the Time of Initiation of Androgen Deprivation Therapy and Time to Progression in Patients With Hormone-Sensitive Prostate Cancer. (2015) (130)
Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time. (2008) (126)
Observation Versus Initial Treatment for Men With Localized, Low-Risk Prostate Cancer (2013) (126)
The CAG repeat within the androgen receptor gene and benign prostatic hyperplasia. (1999) (125)
Evaluation of the 8q24 prostate cancer risk locus and MYC expression. (2009) (123)
Long-term Follow-up of a Randomized Trial of Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer. (2015) (122)
Time to prostate‐specific antigen nadir independently predicts overall survival in patients who have metastatic hormone‐sensitive prostate cancer treated with androgen‐deprivation therapy (2009) (121)
Two differentially expressed genes in normal human prostate tissue and in carcinoma. (1996) (121)
Overexpression of the Long Non-coding RNA SChLAP1 Independently Predicts Lethal Prostate Cancer. (2016) (119)
Prostate-Specific Antigen Screening After 2012 US Preventive Services Task Force Recommendations. (2015) (118)
Development of multinuclear polymeric nanoparticles as robust protein nanocarriers. (2014) (117)
Racial differences in screening for prostate cancer in the elderly. (2004) (115)
Phase I/II Study of Vaccination With Electrofused Allogeneic Dendritic Cells/Autologous Tumor-derived Cells in Patients With Stage IV Renal Cell Carcinoma (2007) (114)
Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer (2008) (114)
Vitamin D receptor protein expression in tumor tissue and prostate cancer progression. (2011) (113)
Radiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: COU-AA-302 results. (2015) (112)
Immunohistochemical expression of BRCA1 and lethal prostate cancer. (2010) (112)
Comparison of Prostate-Specific Membrane Antigen–Based 18F-DCFBC PET/CT to Conventional Imaging Modalities for Detection of Hormone-Naïve and Castration-Resistant Metastatic Prostate Cancer (2016) (111)
Humoral Immune Response against Nontargeted Tumor Antigens after Treatment with Sipuleucel-T and Its Association with Improved Clinical Outcome (2015) (110)
Prostate cancer, version 1.2014. (2013) (108)
Genetic and functional analyses implicate the NUDT11, HNF1B, and SLC22A3 genes in prostate cancer pathogenesis (2012) (106)
CML66, a broadly immunogenic tumor antigen, elicits a humoral immune response associated with remission of chronic myelogenous leukemia (2001) (106)
The androgen receptor gene GGN microsatellite and prostate cancer risk. (1998) (105)
Resistance to docetaxel in prostate cancer is associated with androgen receptor activation and loss of KDM5D expression (2016) (105)
The androgen receptor CAG repeat polymorphism and risk of breast cancer in the Nurses' Health Study. (2002) (105)
A whole-blood RNA transcript-based prognostic model in men with castration-resistant prostate cancer: a prospective study. (2012) (104)
Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell testicular tumors. (1999) (104)
Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study. (2005) (103)
Immunotherapy for the treatment of prostate cancer (2011) (102)
Is adjuvant chemotherapy necessary for patients with stage B1 testicular cancer? (1990) (102)
Adrenal Androgen Levels as Predictors of Outcome in Prostate Cancer Patients Treated with Ketoconazole Plus Antiandrogen Withdrawal: Results from a Cancer and Leukemia Group B Study (2007) (99)
A Large Prospective Study of SEP15 Genetic Variation, Interaction with Plasma Selenium Levels, and Prostate Cancer Risk and Survival (2010) (97)
ChemoRad nanoparticles: a novel multifunctional nanoparticle platform for targeted delivery of concurrent chemoradiation. (2010) (96)
The V89L Polymorphism in the 5α-Reductase Type 2 Gene and Risk of Prostate Cancer (1999) (95)
Association of AR-V7 and Prostate-Specific Antigen RNA Levels in Blood with Efficacy of Abiraterone Acetate and Enzalutamide Treatment in Men with Prostate Cancer (2016) (93)
The altered expression of MiR‐221/‐222 and MiR‐23b/‐27b is associated with the development of human castration resistant prostate cancer (2012) (93)
BRAF mutations in metanephric adenoma of the kidney. (2012) (93)
NCCN Prostate Cancer Practice Guidelines. The National Comprehensive Cancer Network. (1996) (93)
Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell testicular cancer: a long-term update. (2003) (92)
Prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgen-independent prostate cancer. (2004) (91)
Plasma levels of heat shock protein 70 in patients with prostate cancer: a potential biomarker for prostate cancer. (2004) (91)
Racial Differences in the Surgical Care of Medicare Beneficiaries With Localized Prostate Cancer. (2016) (91)
The relationship between a polymorphism in CYP17 with plasma hormone levels and prostate cancer. (2001) (91)
CML28 is a broadly immunogenic antigen, which is overexpressed in tumor cells. (2002) (90)
Analysis of the 10q11 Cancer Risk Locus Implicates MSMB and NCOA4 in Human Prostate Tumorigenesis (2010) (89)
Chemotherapy for prostate cancer. (2002) (88)
Nonpalpable intratesticular masses detected sonographically. (1995) (88)
Regulation of S100P expression by androgen (1996) (87)
Expression of a human complementary DNA for the multidrug resistance gene in murine hematopoietic precursor cells with the use of retroviral gene transfer. (1990) (86)
Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer. (2008) (85)
Acupuncture Versus Cognitive Behavioral Therapy for Insomnia in Cancer Survivors: A Randomized Clinical Trial. (2019) (84)
Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC) (2018) (84)
Phase II Study of Androgen Synthesis Inhibition with Ketoconazole, Hydrocortisone, and Dutasteride in Asymptomatic Castration-Resistant Prostate Cancer (2009) (82)
High-fat diet fuels prostate cancer progression by rewiring the metabolome and amplifying the MYC program (2019) (82)
Prognostic significance of detection of prostate-specific antigen transcripts in the peripheral blood of patients with metastatic androgen-independent prostatic carcinoma. (1997) (81)
Activity of the herbal combination, PC-SPES, in the treatment of patients with androgen-independent prostate cancer. (2001) (81)
FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder (2014) (81)
Feasibility of radical prostatectomy after neoadjuvant chemohormonal therapy for patients with high risk or locally advanced prostate cancer: results of a phase I/II study. (2004) (80)
Androgen receptor mediates the expression of UDP‐glucuronosyltransferase 2 B15 and B17 genes (2008) (79)
A Novel Mechanism Driving Poor-Prognosis Prostate Cancer: Overexpression of the DNA Repair Gene, Ribonucleotide Reductase Small Subunit M2 (RRM2) (2019) (78)
Modification of the association between obesity and lethal prostate cancer by TMPRSS2:ERG. (2013) (78)
Surrogate endpoints for prostate cancer-specific mortality after radiotherapy and androgen suppression therapy in men with localised or locally advanced prostate cancer: an analysis of two randomised trials. (2012) (76)
Plasma selenium, manganese superoxide dismutase, and intermediate- or high-risk prostate cancer. (2009) (76)
Oncogenic Genomic Alterations, Clinical Phenotypes, and Outcomes in Metastatic Castration-Sensitive Prostate Cancer (2020) (76)
Finasteride and flutamide as potency-sparing androgen-ablative therapy for advanced adenocarcinoma of the prostate. (1997) (75)
Prostate cancer : principles and practice (2002) (75)
Phase II trial of RAD001 and bicalutamide for castration‐resistant prostate cancer (2012) (75)
Laparoscopic retroperitoneal lymphadenectomy: multi-institutional analysis. (1994) (73)
Prospective enterprise-level molecular genotyping of a cohort of cancer patients. (2014) (73)
Neoadjuvant Enzalutamide Prior to Prostatectomy (2016) (72)
Influence of androgen deprivation therapy on all-cause mortality in men with high-risk prostate cancer and a history of congestive heart failure or myocardial infarction. (2012) (72)
Aneuploidy drives lethal progression in prostate cancer (2019) (71)
A Phase II Trial of Flavopiridol (NSC #649890) in Patients with Previously Untreated Metastatic Androgen-Independent Prostate Cancer (2004) (70)
In utero gene transfer and expression: a sheep transplantation model. (1989) (69)
Synergistic cytotoxicity of irinotecan and cisplatin in dual-drug targeted polymeric nanoparticles. (2012) (69)
Targeted androgen pathway suppression in localized prostate cancer: a pilot study. (2014) (69)
NCCN Practice Guidelines for Prostate Cancer. (2000) (69)
Risk of prostate cancer recurrence in men treated with radiation alone or in conjunction with combined or less than combined androgen suppression therapy. (2008) (68)
SPINK1 Protein Expression and Prostate Cancer Progression (2014) (68)
A polymorphism of the 5 alpha-reductase gene and its association with prostate cancer: a case-control analysis. (1997) (67)
Platinum-Based Chemotherapy in Metastatic Prostate Cancer With DNA Repair Gene Alterations. (2020) (67)
Elevated IL‐8, TNF‐α, and MCP‐1 in men with metastatic prostate cancer starting androgen‐deprivation therapy (ADT) are associated with shorter time to castration‐resistance and overall survival (2014) (66)
A phase II study of mifepristone (RU‐486) in castration‐resistant prostate cancer, with a correlative assessment of androgen‐related hormones (2008) (65)
Neoplasms of the Prostate (2003) (64)
Prospective evaluation of analgesic use and risk of renal cell cancer. (2011) (64)
The Development of Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP). (2015) (64)
Development of an integrated prostate cancer research information system. (2006) (64)
Neoadjuvant docetaxel followed by radical prostatectomy in patients with high-risk localized prostate cancer: a preliminary report. (2001) (63)
Pheromonal Induction of Spatial Learning in Mice (2013) (62)
Effect of neoadjuvant abiraterone acetate (AA) plus leuprolide acetate (LHRHa) on PSA, pathological complete response (pCR), and near pCR in localized high-risk prostate cancer (LHRPC): Results of a randomized phase II study. (2012) (62)
Response to second-line chemotherapy in patients with hormone refractory prostate cancer receiving two sequences of mitoxantrone and taxanes. (2006) (61)
Patients with Biopsy Gleason 9 and 10 Prostate Cancer Have Significantly Worse Outcomes Compared to Patients with Gleason 8 Disease. (2015) (60)
Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry (2020) (59)
Racial Differences in Genomic Profiling of Prostate Cancer. (2020) (59)
Antiandrogens in Prostate Cancer (2004) (59)
Production of glycosylated physiologically "normal" human alpha 1-antitrypsin by mouse fibroblasts modified by insertion of a human alpha 1-antitrypsin cDNA using a retroviral vector. (1987) (59)
Pan-cancer Analysis of CDK12 Alterations Identifies a Subset of Prostate Cancers with Distinct Genomic and Clinical Characteristics. (2020) (58)
Utilizing predictions of early prostate-specific antigen failure to optimize patient selection for adjuvant systemic therapy trials. (2000) (58)
The DHEA-sulfate depot following P450c17 inhibition supports the case for AKR1C3 inhibition in high risk localized and advanced castration resistant prostate cancer. (2015) (56)
The androgen receptor CAG repeat polymorphism and its relationship to prostate cancer. (1998) (55)
Revised Overall Survival Analysis of a Phase II, Randomized, Double-Blind, Controlled Study of PROSTVAC in Men With Metastatic Castration-Resistant Prostate Cancer. (2017) (54)
Evaluation of 8q24 and 17q Risk Loci and Prostate Cancer Mortality (2009) (53)
Significance of BRCA2 and RB1 Co-loss in Aggressive Prostate Cancer Progression (2019) (53)
Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohort study. (2013) (53)
Genome-wide Association Study of Prostate Cancer Mortality (2010) (53)
Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high‐risk localized prostate cancer (2012) (53)
CAG repeat within the androgen receptor gene and incidence of surgery for benign prostatic hyperplasia in U.S. physicians (1999) (53)
Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in men with hormone-refractory prostate cancer. (2001) (52)
Prostate Cancer Immunotherapy (2011) (51)
Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in metastatic prostate cancer: a nested study within CALGB 9583. (2003) (51)
A Transient Increase in Eosinophils Is Associated with Prolonged Survival in Men with Metastatic Castration-Resistant Prostate Cancer Who Receive Sipuleucel-T (2014) (50)
The likelihood of death from prostate cancer in men with favorable or unfavorable intermediate‐risk disease (2014) (50)
Radiation with or without 6 months of androgen suppression therapy in intermediate- and high-risk clinically localized prostate cancer: a postrandomization analysis by risk group. (2010) (49)
PLZF, a tumor suppressor genetically lost in metastatic castration-resistant prostate cancer, is a mediator of resistance to androgen deprivation therapy. (2015) (49)
Association of Prostate Cancer Risk Loci with Disease Aggressiveness and Prostate Cancer–Specific Mortality (2011) (49)
Suicidal ideation in prostate cancer survivors: Understanding the role of physical and psychological health outcomes (2014) (49)
A prognostic score for hormone-refractory prostate cancer: analysis of two cancer and leukemia group B studies. (1999) (49)
The IMAAGEN Study: Effect of Abiraterone Acetate and Prednisone on Prostate Specific Antigen and Radiographic Disease Progression in Patients with Nonmetastatic Castration Resistant Prostate Cancer (2018) (49)
Integrative Analysis of 1q23.3 Copy-Number Gain in Metastatic Urothelial Carcinoma (2014) (48)
Role of diet in prostate cancer: the epigenetic link (2014) (47)
Real‐world outcomes of sipuleucel‐T treatment in PROCEED, a prospective registry of men with metastatic castration‐resistant prostate cancer (2019) (47)
Association of HSD3B1 Genotype With Response to Androgen-Deprivation Therapy for Biochemical Recurrence After Radiotherapy for Localized Prostate Cancer (2017) (47)
Selenium- or Vitamin E–Related Gene Variants, Interaction with Supplementation, and Risk of High-Grade Prostate Cancer in SELECT (2016) (47)
Associations of prostate cancer risk variants with disease aggressiveness: results of the NCI-SPORE Genetics Working Group analysis of 18,343 cases (2015) (46)
Causes of death in men undergoing androgen suppression therapy for newly diagnosed localized or recurrent prostate cancer (2008) (45)
Functional analysis of single cells identifies a rare subset of circulating tumor cells with malignant traits. (2014) (45)
Selective aromatase inhibition for patients with androgen‐independent prostate carcinoma (2002) (44)
Single‐nucleotide polymorphisms within the antioxidant defence system and associations with aggressive prostate cancer (2011) (44)
Randomized phase II study of atrasentan alone or in combination with zoledronic acid in men with metastatic prostate cancer (2006) (44)
Measurement of plasma levels of vascular endothelial growth factor in prostate cancer patients: relationship with clinical stage, Gleason score, prostate volume, and serum prostate-specific antigen. (2006) (43)
Prognostic significance of plasma scatter factor/hepatocyte growth factor levels in patients with metastatic hormone- refractory prostate cancer: results from cancer and leukemia group B 150005/9480. (2006) (43)
Response to docetaxel/carboplatin‐based chemotherapy as first‐ and second‐line therapy in patients with metastatic hormone‐refractory prostate cancer (2008) (42)
ATR inhibition controls aggressive prostate tumors deficient in Y‐linked histone demethylase KDM5D (2018) (42)
Overview consensus statement. Newer approaches to androgen deprivation therapy in prostate cancer. (2002) (42)
Clinical implementation of integrated whole-genome copy number and mutation profiling for glioblastoma. (2015) (41)
Response to low‐dose ketoconazole and subsequent dose escalation to high‐dose ketoconazole in patients with androgen‐independent prostate cancer (2006) (40)
Synchronous adenocarcinoma and transitional cell carcinoma of the bladder associated with augmentation: case report and review of the literature. (1993) (40)
CT and pathologic predictive features of residual mass histologic findings after chemotherapy for nonseminomatous germ cell tumors: can residual malignancy or teratoma be excluded? (1991) (40)
Predicting outcomes in prostate cancer: how many more nomograms do we need? (2007) (40)
Elevated insulin‐like growth factor binding protein‐1 (IGFBP‐1) in men with metastatic prostate cancer starting androgen deprivation therapy (ADT) is associated with shorter time to castration resistance and overall survival (2014) (40)
Diversity of Enrollment in Prostate Cancer Clinical Trials: Current Status and Future Directions (2020) (40)
Post prostatectomy outcomes of patients with high-risk prostate cancer treated with neoadjuvant androgen blockade (2018) (39)
Interval to testosterone recovery after hormonal therapy for prostate cancer and risk of death. (2009) (39)
Impact of new systemic therapies on overall survival of patients with metastatic castration-resistant prostate cancer in a hospital-based registry (2019) (38)
No association between the I105V polymorphism of the glutathione S-transferase P1 gene (GSTP1) and prostate cancer risk: a prospective study. (2000) (38)
Surrogate End Points for All-Cause Mortality in Men With Localized Unfavorable-Risk Prostate Cancer Treated With Radiation Therapy vs Radiation Therapy Plus Androgen Deprivation Therapy: A Secondary Analysis of a Randomized Clinical Trial (2017) (38)
Contemporary nationwide patterns of self-reported prostate-specific antigen screening. (2014) (38)
Absence of a correlation of androgen receptor gene CAG repeat length and prostate cancer risk in an African-American population. (2004) (38)
Single-Nucleotide Polymorphisms in p53 Pathway and Aggressiveness of Prostate Cancer in a Caucasian Population (2010) (38)
Gene transfer into hematopoietic progenitor cells from normal and cyclic hematopoietic dogs using retroviral vectors. (1988) (37)
Prognostic indicators in hormone refractory prostate cancer. (1999) (37)
Treatment of locally advanced prostate cancer: is chemotherapy the next step? (1999) (37)
Elevated plasma tissue inhibitor of metalloproteinase‐1 levels predict decreased survival in castration‐resistant prostate cancer patients (2011) (36)
Active Surveillance for Early-stage Prostate Cancer Review of the Current Literature (2008) (36)
Impact of symptomatic skeletal events on health-care resource utilization and quality of life among patients with castration-resistant prostate cancer and bone metastases (2017) (36)
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma (2016) (36)
Recent progress in management of advanced prostate cancer. (2005) (36)
Effectiveness of Electroacupuncture or Auricular Acupuncture vs Usual Care for Chronic Musculoskeletal Pain Among Cancer Survivors: The PEACE Randomized Clinical Trial. (2021) (35)
A phase I study of everolimus and docetaxel in patients with castration-resistant prostate cancer. (2015) (35)
CAG repeat within the androgen receptor gene and incidence of surgery for benign prostatic hyperplasia in U.S. physicians. (1999) (35)
The joint effect of smoking and AIB1 on breast cancer risk in BRCA1 mutation carriers. (2006) (35)
Prostate cancer incidence and mortality among men using statins and non-statin lipid-lowering medications. (2018) (35)
The role of sipuleucel-T in therapy for castration-resistant prostate cancer: a critical analysis of the literature. (2012) (34)
Advances in the treatment of prostate cancer. (2007) (34)
Phase 1 study of PSMA ADC, an antibody‐drug conjugate targeting prostate‐specific membrane antigen, in chemotherapy‐refractory prostate cancer (2019) (32)
TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort (2007) (32)
Vinorelbine and estramustine in androgen‐independent metastatic prostate cancer (2000) (32)
Recombinant human granulocyte-macrophage colony-stimulating factor as an adjunct to conventional-dose ifosfamide-based chemotherapy for patients with advanced or relapsed germ cell tumors: a randomized trial. (1995) (31)
Meningeal carcinomatosis from transitional cell carcinoma of the bladder (1993) (31)
Finasteride and flutamide therapy in patients with advanced prostate cancer: response to subsequent castration and long-term follow-up. (2003) (30)
The Impact of Common Genetic Variations in Genes of the Sex Hormone Metabolic Pathways on Steroid Hormone Levels and Prostate Cancer Aggressiveness (2011) (30)
Radical prostatectomy lowers plasma vascular endothelial growth factor levels in patients with prostate cancer. (2004) (30)
The Prostate Cancer Working Group 3 (PCWG3) consensus for trials in castration-resistant prostate cancer (CRPC). (2015) (30)
Predictors of survival in patients with prostate cancer and spinal metastasis. Presented at the 2009 Joint Spine Section Meeting. Clinical article. (2010) (30)
Prostate Cancer Risk and ESR1 TA, ESR2 CA Repeat Polymorphisms (2007) (30)
Retroviral-mediated gene transfer into mammalian cells. (1987) (30)
The TMPRSS 2 : ERG Rearrangement , ERG Expression , and Prostate Cancer Outcomes : A Cohort Study and Meta-analysis (2012) (30)
Prognostic Index Model for Progression‐Free Survival in Chemotherapy‐Naïve Metastatic Castration‐Resistant Prostate Cancer Treated With Abiraterone Acetate Plus Prednisone (2017) (29)
Androgen Deprivation Therapy Is Associated With Prolongation of QTc Interval in Men With Prostate Cancer (2018) (29)
Finasteride and bicalutamide as primary hormonal therapy in patients with advanced adenocarcinoma of the prostate. (2004) (29)
Uremic levels of oxalic acid suppress replication and migration of human endothelial cells. (1990) (29)
Mortality and Hospitalization Risk Following Oral Androgen Signaling Inhibitors Among Men with Advanced Prostate Cancer by Pre-existing Cardiovascular Comorbidities. (2020) (29)
Imaging, procedural and clinical variables associated with tumor yield on bone biopsy in metastatic castration-resistant prostate cancer (2014) (29)
Association of SLCO2B1 Genotypes With Time to Progression and Overall Survival in Patients Receiving Androgen-Deprivation Therapy for Prostate Cancer. (2016) (28)
Peroxisome Proliferator-Activated Receptor Gamma (PPARγ as a Novel Target for Prostate Cancer (2002) (28)
A Randomized Phase II Trial of Short-Course Androgen Deprivation Therapy With or Without Bevacizumab for Patients With Recurrent Prostate Cancer After Definitive Local Therapy. (2016) (28)
Multicenter phase II study of trabectedin in patients with metastatic castration-resistant prostate cancer. (2012) (28)
A phase I study of estramustine, weekly docetaxel, and carboplatin chemotherapy in patients with hormone-refractory prostate cancer. (2005) (28)
Androgen receptor-mediated downregulation of microRNA-221 and -222 in castration-resistant prostate cancer (2017) (28)
Expression of lncRNA MIR222HG co-transcribed from the miR-221/222 gene promoter facilitates the development of castration-resistant prostate cancer (2018) (28)
Novel RB1-Loss Transcriptomic Signature Is Associated with Poor Clinical Outcomes across Cancer Types (2019) (28)
Smoking and alcohol use may be risk factors for poorer outcome in patients with clear cell renal carcinoma. (2000) (27)
Randomized, double-blind, vector-controlled study of targeted immunotherapy in patients (pts) with hormone-refractory prostate cancer (HRPC). (2006) (27)
Androgen Receptor CAG Repeat Polymorphism and Risk of TMPRSS2:ERG–Positive Prostate Cancer (2014) (27)
The role of tumor metabolism as a driver of prostate cancer progression and lethal disease: results from a nested case-control study (2016) (27)
Role of microRNA-221/-222 in cancer development and progression (2009) (27)
A Phase II Trial of Abiraterone Combined with Dutasteride for Men with Metastatic Castration-Resistant Prostate Cancer (2016) (27)
Department of Defense prostate cancer clinical trials consortium: a new instrument for prostate cancer clinical research. (2009) (27)
Event-Free Survival, a Prostate-Specific Antigen-Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation. (2020) (26)
Effects of Androgen Deprivation Therapy on Pain Perception, Quality of Life, and Depression in Men With Prostate Cancer. (2017) (26)
Expression Levels of DNA Damage Repair Proteins Are Associated With Overall Survival in Platinum-Treated Advanced Urothelial Carcinoma. (2016) (26)
Prostate-specific membrane antigen antibody drug conjugate (PSMA ADC): A phase I trial in metastatic castration-resistant prostate cancer (mCRPC) previously treated with a taxane. (2013) (26)
Predictors of Prostate Cancer Tissue Acquisition by an Undirected Core Bone Marrow Biopsy in Metastatic Castration-Resistant Prostate Cancer—A Cancer and Leukemia Group B Study (2005) (26)
Statin Use Is Associated with Lower Risk of PTEN-Null and Lethal Prostate Cancer (2019) (26)
Activity of ketoconazole after taxane‐based chemotherapy in castration‐resistant prostate cancer (2009) (26)
Application of Oligonucleotide Microarrays to Assess the Biological Effects of Neoadjuvant Imatinib Mesylate Treatment for Localized Prostate Cancer (2006) (26)
The V89L polymorphism in the 5alpha-reductase type 2 gene and risk of prostate cancer. (1999) (25)
Posttreatment prostate specific antigen nadir predicts prostate cancer specific and all cause mortality. (2012) (25)
Castration Resistance in Prostate Cancer Is Mediated by the Kinase NEK6. (2017) (25)
Testicular cancer. Clinical practice guidelines in oncology. (2006) (24)
Testing a Multigene Signature of Prostate Cancer Death in the Swedish Watchful Waiting Cohort (2008) (24)
Noise and bias in microarray analysis of tumor specimens. (2006) (24)
Time to disease-related pain and first opioid use in patients with metastatic castration-resistant prostate cancer treated with sipuleucel-T (2014) (24)
Survival following radiation and androgen suppression therapy for prostate cancer in healthy older men: implications for screening recommendations. (2010) (23)
Debrisoquine hydroxylase (CYP2D6) and prostate cancer. (1998) (23)
Impact of prior ketoconazole therapy on response proportion to abiraterone acetate, a 17-alpha hydroxylase C17,20-lyase inhibitor in castration resistant prostate cancer (CRPC) (2008) (23)
(18)F-FDG-PET/CT and (18)F-NaF-PET/CT in men with castrate-resistant prostate cancer. (2015) (23)
DNA copy number analysis of metastatic urothelial carcinoma with comparison to primary tumors (2015) (23)
Immunotherapy for castration-resistant prostate cancer. (2012) (23)
Inherited Variations in AR, ESR1, and ESR2 Genes Are Not Associated With Prostate Cancer Aggressiveness or With Efficacy of Androgen Deprivation Therapy (2010) (23)
A Single Nucleotide Polymorphism in Inflammatory Gene RNASEL Predicts Outcome after Radiation Therapy for Localized Prostate Cancer (2012) (23)
Phase II study of low dose and high dose conjugated estrogen for androgen independent prostate cancer. (2007) (22)
Clinical predictors of survival in men with castration‐resistant prostate cancer (2013) (22)
Intravesical therapy for superficial bladder cancer: is it a wash? (1994) (22)
Compensatory increase in levels of beta minor globin in murine beta-thalassemia is under translational control. (1986) (22)
Demystifying Immunotherapy in Prostate Cancer: Understanding Current and Future Treatment Strategies (2013) (22)
Prospects for gene therapy for immunodeficiency diseases. (1988) (22)
Recent advances in immunotherapy for the treatment of prostate cancer (2011) (22)
Efficacy of nilutamide as secondary hormonal therapy in androgen‐independent prostate cancer (2005) (22)
Rate of relapse following treatment for localized prostate cancer: a critical analysis of retrospective reports. (1994) (21)
Initial decline in hemoglobin during neoadjuvant hormonal therapy predicts for early prostate specific antigen failure following radiation and hormonal therapy for patients with intermediate and high‐risk prostate cancer (2002) (21)
A prognostic model for predicting overall survival (OS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA) after docetaxel. (2013) (21)
14‐Day Continuous Infusion of Mitoxantrone in Hormone‐Refractory Metastatic Adenocarcinoma of the Prostate (1993) (21)
Physical and emotional health information needs and preferences of long-term prostate cancer survivors. (2016) (21)
Activity of dutasteride plus ketoconazole in castration-refractory prostate cancer after progression on ketoconazole alone. (2009) (21)
p53 protein expression status and recurrence in men treated with radiation and androgen suppression therapy for higher-risk prostate cancer: a prospective phase II Cancer and Leukemia Group B Study (CALGB 9682). (2008) (20)
New agents in the therapy of hormone-refractory patients with prostate cancer. (1995) (20)
Inherited Variants in the Chemokine CCL2 Gene and Prostate Cancer Aggressiveness in a Caucasian Cohort (2010) (20)
The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate‐resistant prostate cancer (2013) (20)
Prostate-specific antigen test for prostate cancer screening: American Society of Clinical Oncology provisional clinical opinion. (2012) (20)
Amplified in breast cancer-1 glutamine repeat and prostate cancer risk (2000) (19)
Hormonal perturbations in patients with testicular cancer treated with cisplatin (1992) (19)
Role of androgen deprivation therapy in early salvage radiation among patients with prostate-specific antigen level of 0.5 or less. (2015) (19)
Androgen Deprivation Therapy Reversibly Increases Endothelium‐Dependent Vasodilation in Men With Prostate Cancer (2015) (19)
Phase I trial of RAD001 (R) and docetaxel (D) in castration resistant prostate cancer (CRPC) with FDG-PET assessment of RAD001 activity (2008) (19)
PTEN polymorphism (IVS4) is not associated with risk of prostate cancer. (2001) (19)
Emerging players in prostate cancer: long non-coding RNAs. (2014) (19)
Association of genetic variations of selenoprotein genes, plasma selenium levels, and prostate cancer aggressiveness at diagnosis (2016) (19)
Overall survival (OS) analysis of a phase II randomized controlled trial (RCT) of a poxviral-based PSA targeted immunotherapy in metastatic castration-resistant prostate cancer (mCRPC). (2009) (19)
Mutations in ribonuclease L gene do not occur at a greater frequency in patients with familial prostate cancer compared with patients with sporadic prostate cancer. (2003) (18)
Predictors of survival in patients with prostate cancer and spinal metastasis: Clinical article (2010) (18)
Male Patients with Diagnoses of Both Breast Cancer and Prostate Cancer (2003) (18)
Importance of serum hemoglobin in hormone refractory prostate cancer. (2002) (18)
Prediagnostic Plasma Vascular Endothelial Growth Factor Levels and Risk of Prostate Cancer (2005) (18)
Evaluating the combined effect of comorbidity and prostate-specific antigen kinetics on the risk of death in men after prostate-specific antigen recurrence. (2009) (18)
Duration of short-course androgen suppression therapy and the risk of death as a result of prostate cancer. (2011) (18)
Differentiating agents and the treatment of prostate cancer: Vitamin D3 and peroxisome proliferator-activated receptor gamma ligands. (2003) (18)
The impact of statin use on the efficacy of abiraterone acetate in patients with castration‐resistant prostate cancer (2017) (18)
Cooperative group tissue banks as research resources: the cancer and leukemia group B tissue repositories. (2002) (17)
Mechanisms responsible for reduced erythropoiesis during androgen deprivation therapy in men with prostate cancer. (2018) (17)
Other novel agents: Rationale and current status as chemopreventive agents. (2001) (17)
Effects of G/A polymorphism, rs266882, in the androgen response element 1 of the PSA gene on prostate cancer risk, survival and circulating PSA levels (2008) (17)
HYDROCORTISONE (H) WITH OR WITHOUT MITOXANTRONE (M) IN MEN WITH HORMONE REFRACTORY PROSTATE CANCER (HRPC). THE RESULTS OF CALGB 9182 (1999) (17)
Secondary hormonal therapy in men with castration-resistant prostate cancer. (2011) (17)
Phase II study of three hour, weekly infusion of trabectedin (ET-743) in men with metastatic, androgen-independent prostate carcinoma (AIPC) (2005) (17)
Re: interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer. (2012) (17)
Gene transfer and expression in nonhuman primates using retroviral vectors. (1986) (17)
Measuring PI3K Activation: Clinicopathologic, Immunohistochemical, and RNA Expression Analysis in Prostate Cancer (2015) (17)
Cabozantinib Inhibits Abiraterone's Upregulation of IGFIR Phosphorylation and Enhances Its Anti–Prostate Cancer Activity (2015) (16)
Treatment of Metastatic Prostate Cancer in 2018. (2019) (16)
Identifying suicidal symptoms in prostate cancer survivors using brief self-report (2015) (16)
Erratum: TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort (Oncogene (2007) 26, (4596-4599) DOI: 10.1038/sj.onc.1210237) (2007) (16)
Clinical Outcomes of First‐line Abiraterone Acetate or Enzalutamide for Metastatic Castration‐resistant Prostate Cancer After Androgen Deprivation Therapy + Docetaxel or ADT Alone for Metastatic Hormone‐sensitive Prostate Cancer (2017) (16)
Differences in Prostate Cancer Genomes by Self-reported Race: Contributions of Genetic Ancestry, Modifiable Cancer Risk Factors, and Clinical Factors (2021) (15)
Docetaxel (Taxotere)-based chemotherapy for hormone-refractory and locally advanced prostate cancer. (1999) (15)
Effects of a gift certificate incentive and specialized delivery on prostate cancer survivors' response rate to a mailed survey: a randomized-controlled trial. (2014) (15)
Tight binding inhibitors--IX. Kinetic parameters of dihydrofolate reductase inhibited by methotrexate, an example of equilibrium study. (1981) (15)
Prostate-Specific Antigen Failure and Risk of Death Within Comorbidity Subgroups Among Men With Unfavorable-Risk Prostate Cancer Treated in a Randomized Trial. (2016) (15)
Prospect: A randomized double-blind phase 3 efficacy study of PROSTVAC-VF immunotherapy in men with asymptomatic/minimally symptomatic metastatic castration-resistant prostate cancer. (2015) (15)
Impact of 5α‐reductase inhibitor and α‐blocker therapy for benign prostatic hyperplasia on prostate cancer incidence and mortality (2018) (15)
Time to disease-related pain after sipuleucel-T in asymptomatic patients with metastatic castrate-resistant prostate cancer (mCRPC): Results from three randomized phase III trials. (2011) (15)
Response to second-line chemotherapy in patients with hormone refractory prostate cancer (HRPC) receiving two sequences of mitoxantrone (M) and taxanes (T) (2005) (15)
Population‐based patterns of prescription androgen use, 1976–2008 (2014) (15)
Prognostic Significance of Baseline Reverse Transcriptase-PCR for Prostate-Specific Antigen in Men with Hormone-Refractory Prostate Cancer Treated with Chemotherapy (2005) (15)
Attempts at Gene Therapy in β‐Thalassemic Mice (1985) (14)
Obesity and the Odds of Weight Gain following Androgen Deprivation Therapy for Prostate Cancer (2014) (14)
Microsatellite instability in prostate cancer and response to immune checkpoint blockade. (2018) (14)
Nine-Gene Molecular Signature Is Not Associated with Prostate Cancer Death in a Watchful Waiting Cohort (2008) (14)
Integration of immunotherapy into the management of advanced prostate cancer. (2012) (14)
Bone directed therapies for prostate cancer. (2007) (14)
Genotyping and functional analysis of the D104N variant of human endostatin (2004) (14)
Integrative Clinical Genomics of Advanced Prostate Cancer Graphical (2015) (14)
Simultaneous and exact interval estimates for the contrast of two groups based on an extremely high dimensional variable: application to mass spec data (2007) (14)
Intratumoral Sterol-27-Hydroxylase (CYP27A1) Expression in Relation to Cholesterol Synthesis and Vitamin D Signaling and Its Association with Lethal Prostate Cancer (2019) (14)
Effects of acupuncture versus cognitive behavioral therapy on cognitive function in cancer survivors with insomnia: A secondary analysis of a randomized clinical trial (2020) (14)
Assessment of prostate cancer volume using endorectal coil magnetic resonance imaging: a new predictor of tumor response to neoadjuvant androgen suppression therapy. (1998) (13)
Gene expression profiling of prostate tissue identifies chromatin regulation as a potential link between obesity and lethal prostate cancer (2017) (13)
Results of PROSPECT: A randomized phase 3 trial of PROSTVAC-V/F (PRO) in men with asymptomatic or minimally symptomatic metastatic, castration-resistant prostate cancer. (2018) (13)
The role of miRNAs in prostate cancer. (2015) (13)
Efficacy of nilutamide as secondary hormonal therapy in androgen-independent prostate cancer. (2005) (13)
Duration of Androgen Deprivation Therapy for High-Risk Prostate Cancer: Application of Randomized Trial Data in a Tertiary Referral Cancer Center. (2016) (13)
Comparing prostate specific antigen outcomes after different types of radiotherapy management of clinically localized prostate cancer highlights the importance of controlling for established prognostic factors. (2000) (13)
Effect of finasteride on risk of prostate cancer: How little we really know (2004) (13)
CD38 in Advanced Prostate Cancers (2021) (12)
Predictors of duration of abiraterone acetate in men with castration-resistant prostate cancer (2016) (12)
Third international conference on innovations and challenges in prostate cancer: prevention, detection and treatment. (2003) (12)
Radiation and Androgen Deprivation Therapy With or Without Docetaxel in the Management of Nonmetastatic Unfavorable-Risk Prostate Cancer: A Prospective Randomized Trial (2021) (12)
Inferences about drug safety in phase 3 trials in oncology: Examples from advanced prostate cancer. (2020) (12)
Polymorphism in endostatin, an angiogenesis inhibitor, and prostate cancer risk and survival: A prospective study (2009) (12)
Eleventh Prouts Neck Meeting on Prostate Cancer: emerging strategies in prostate cancer therapy. (2007) (12)
Comorbidity, body mass index, and age and the risk of nonprostate‐cancer‐specific mortality after a postradiation prostate‐specific antigen recurrence (2010) (12)
Symposium on Androgen Action in Prostate Cancer (2004) (12)
Surgical and medical management of germ cell tumors of the chest. (1993) (12)
Ribonucleotide reductase small subunit M2 is a master driver of aggressive prostate cancer (2020) (12)
Prostate-specific membrane antigen antibody drug conjugate (PSMA ADC): A phase I trial in taxane-refractory prostate cancer. (2011) (12)
Letters to the Editor/Errata Re: Early Detection of Prostate Cancer: AUA guideline (2013) (11)
Risk of all-cause and prostate cancer-specific mortality after brachytherapy in men with small prostate size. (2011) (11)
Attenuation of SRC Kinase Activity Augments PARP Inhibitor–mediated Synthetic Lethality in BRCA2-altered Prostate Tumors (2020) (11)
Liver metastases (LM) to predict for short overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts). (2012) (11)
Association between the Met326Ile polymorphism of the p85alpha regulatory subunit of phosphatidylinositol 3-kinase and prostate cancer risk: a prospective study. (2003) (11)
Effect of abiraterone acetate and low-dose prednisone on PSA in patients with nonmetastatic castration-resistant prostate cancer: The results from IMAAGEN core study. (2014) (11)
Chemotherapy for muscle-infiltrating bladder cancer. (1992) (11)
Annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: A randomized placebo-controlled trial. (2006) (11)
Gallium-67-citrate imaging in extragonadal and gonadal seminomas: relationship to radiologic findings. (1994) (11)
Interim safety and efficacy results from a phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma. (2004) (11)
Inhibition of EZH2 transactivation function sensitizes solid tumors to genotoxic stress (2022) (11)
Optimal timing of sipuleucel-T treatment in metastatic castration-resistant prostate cancer. (2015) (11)
Rapid rise of serum prostate specific antigen levels after discontinuation of the herbal therapy PC‐SPES in patients with advanced prostate carcinoma (2002) (11)
Prognostic index model (PIM) for overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) without prior chemotherapy treated with abiraterone acetate (AA). (2015) (10)
Identification of ALK Gene Alterations in Urothelial Carcinoma (2014) (10)
Hormone-refractory prostate cancer: choosing the appropriate treatment option. (2007) (10)
Phase I study of the novel, oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK): Evaluating the pharmacokinetic effect of a high-fat meal in patients with hormone-refractory prostate cancer (HRPC) (2004) (10)
Antigen spread and survival with sipuleucel-T in patients with advanced prostate cancer. (2014) (10)
NCCN practice guidelines for testicular cancer (1998) (10)
IMAAGEN trial safety and efficacy update: Effect of abiraterone acetate and low-dose prednisone on prostate-specific antigen and radiographic disease progression in patients with nonmetastatic castration-resistant prostate cancer. (2016) (10)
Aspirin and hormone therapy for prostate cancer. (2007) (10)
Gene therapy: efforts at developing large animal models for autologous bone marrow transplant and gene transfer with retroviral vectors. (1987) (10)
Progressive sclerosis of isolated foot metastasis of prostate cancer. (2002) (10)
The epidemic of prostate cancer and the medical literature: a causal association? (1998) (10)
Kidney cancer. Clinical practice guidelines in oncology. (2006) (9)
Phase 1 dose-finding study of cabozantinib (cabo) plus abiraterone (abi) combination therapy in castration resistant prostate cancer (CRPC): An investigator-sponsored study. (2014) (9)
Metastasis free survival (MFS) is a surrogate for overall survival (OS) in localized prostate cancer (CaP) (2016) (9)
The prostate specific antigen. Its use as a tumor marker for prostate cancer. (1994) (9)
Staging and Grading (2003) (9)
A phase Ib study of BKM120 combined with abiraterone acetate for castrate-resistant, metastatic prostate cancer. (2014) (9)
Late toxicities, long-term follow-up, less intensive treatment: leading issues in the therapy of testis cancer. (1988) (8)
FGFR 3 expression in primary and metastatic urothelial carcinoma of the bladder (2014) (8)
Tackling Diversity in Prostate Cancer Clinical Trials: A Report From the Diversity Working Group of the IRONMAN Registry (2021) (8)
Dual Blockade of c-MET and the Androgen Receptor in Metastatic Castration-resistant Prostate Cancer: A Phase I Study of Concurrent Enzalutamide and Crizotinib (2020) (8)
The likelihood of death from prostate cancer in men with favorable or unfavorable intermediate-risk disease. (2014) (8)
New developments in the management of prostate cancer. (2013) (8)
Adverse event profiles of apalutamide, enzalutamide, and darolutamide in SPARTAN, PROSPER, and ARAMIS: How confident are we about which drug is safest? (2020) (8)
GENETIC DETERMINANTS OF PROSTATE CANCER RISK (2007) (8)
Epidemiology of and Risk Factors for Prostate Cancer (2000) (8)
New agents in metastatic prostate cancer. (2012) (8)
Time to Prostate-specific Antigen Nadir and the Risk of Death From Prostate Cancer Following Radiation and Androgen Deprivation Therapy. (2019) (8)
Germline Variation in Superoxide Dismutase-2 (SOD2) and Survival Outcomes after Radiation Therapy for Prostate Cancer: Results from a Test and Validation Set Analysis (2015) (8)
Docetaxel, bevacizumab, and androgen deprivation therapy for biochemical disease recurrence after definitive local therapy for prostate cancer (2015) (8)
Prevention, complementary therapies, and new scientific developments in the field of prostate cancer. (2006) (8)
Methylation‐associated miR‐193b silencing activates master drivers of aggressive prostate cancer (2019) (8)
Long-term follow-up of a phase II trial of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer. (2013) (8)
Muscle-Invasive Bladder Cancer (2003) (8)
The ABC model of prostate cancer: A conceptual framework for the design and interpretation of prognostic studies (2017) (7)
Carboplatin for stage I seminoma. (2006) (7)
Modification of BRCA 1-and BRCA 2-associated Breast Cancer Risk by AIB 1 Genotype and Reproductive History 1 (2001) (7)
Impact of prior docetaxel (D) on sipuleucel-T (sip-T) product parameters in PROCEED patients (pts). (2013) (7)
IMAAGEN trial update: Effect of abiraterone acetate and low dose prednisone on PSA and radiographic disease progression in patients with non-metastatic castration-resistant prostate cancer. (2015) (7)
PACLITAXEL(T), ESTRAMUSTINE(E) AND CARBOPLATIN(C) IN PATIENTS (Pts) WITH ADVANCED PROSTATE CANCER(PC): (1999) (7)
Low Expression of the Androgen-Induced Tumor Suppressor Gene PLZF and Lethal Prostate Cancer (2019) (7)
Is the Evidence Sufficient to Recommend Statins for All Men With Prostate Cancer? (2017) (7)
No association between a polymorphic variant of the IRS‐1 gene and prostate cancer risk (2008) (7)
Naming disease states for clinical utility in prostate cancer: a rose by any other name might not smell as sweet. (2018) (7)
OVERALL SURVIVAL ANALYSIS OF AFRICAN AMERICAN AND CAUCASIAN PATIENTS RECEIVING SIPULEUCEL‐T: PRELIMINARY DATA FROM THE PROCEED REGISTRY: PD24‐12 (2017) (7)
Multiplex Immunofluorescence in Formalin-Fixed Paraffin-Embedded Tumor Tissue to Identify Single-Cell–Level PI3K Pathway Activation (2020) (6)
A Clinical Evaluation of Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer: Guiding Principles for Treatment Selection and Perspectives on Research (2020) (6)
PROFILE: Broadly based genomic testing for all patients at a major cancer center. (2013) (6)
Clinical roundtable monograph: new and emerging treatments for advanced prostate cancer. (2011) (6)
A phase 2 trial of abiraterone acetate without glucocorticoids for men with metastatic castration‐resistant prostate cancer (2018) (6)
Disease-free survival (DFS) as a surrogate for overall survival (OS) in localized prostate cancer (CaP) (2016) (6)
Neoadjuvant Doxil Chemotherapy Prior to Androgen Ablation Plus Radiotherapy for High-Risk Localized Prostate Cancer: Feasibility and Toxicity (2003) (6)
1 THE TMPRSS 2 : ERG REARRANGEMENT , ERG EXPRESSION , AND PROSTATE CANCER OUTCOMES : A COHORT STUDY AND META-ANALYSIS (2012) (6)
Retroviral-mediated gene transfer into hematopoietic cells. (1986) (6)
A double-blind randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated advanced urothelial cancer. (2011) (6)
Constitutive expression of high levels of prostate-specific antigen in the absence of prostate carcinoma. (1996) (6)
PROTEUS: A randomized, double-blind, placebo (PBO)-controlled, phase 3 trial of apalutamide (APA) plus androgen deprivation therapy (ADT) versus PBO plus ADT prior to radical prostatectomy (RP) in patients with localized high-risk or locally advanced prostate cancer (PC). (2019) (6)
Physician attitudes toward cytotoxic chemotherapy use in patients with advanced prostate carcinoma (2003) (6)
A phase II trial of methotrexate, cisplatin, 5‐fluorouracil, and leucovorin in the treatment of invasive and metastatic urothelial carcinoma (1999) (6)
Predictors of outcome and subgroup results from the integrated analysis of sipuleucel-T trials in metastatic castration-resistant prostate cancer. (2010) (6)
Phase II trial of ketoconazole, hydrocortisone, and dutasteride (KHAD) for castration resistant prostate cancer (CRPC) (2008) (6)
Phase II study of low dose (LD) and high dose (HD) premarin in androgen independent prostate cancer (AIPC). (2006) (6)
Abiraterone Acetate Induces CREB1 Phosphorylation and Enhances the Function of the CBP-p300 Complex, Leading to Resistance in Prostate Cancer Cells (2021) (6)
Overall survival (OS) of African-American (AA) and Caucasian (CAU) men who received sipuleucel-T for metastatic castration-resistant prostate cancer (mCRPC): Final PROCEED analysis. (2019) (6)
Long-term followup of 150 patients with testicular cancer treated at a single institution. (1992) (5)
Author Correction: Restoration of tumour-growth suppression in vivo via systemic nanoparticle-mediated delivery of PTEN mRNA (2018) (5)
Association of genetic variation of the six gene prognostic model for castration‐resistant prostate cancer with survival (2018) (5)
Prostate cancer : a multidisciplinary guide (1997) (5)
Retroviral-mediated gene transfer into hemopoietic cells. (1988) (5)
A Phase II Trial of Interferon-Alpha and Toremifene in Advanced Renal Cell Cancer Patients (2002) (5)
SPINK 1 Protein Expression and Prostate Cancer Progression (2014) (5)
Overall survival (OS) benefit with sipuleucel-T by baseline PSA: An exploratory analysis from the phase III IMPACT trial. (2012) (5)
Platinum-based chemotherapy in metastatic prostate cancer with alterations in DNA damage repair genes. (2019) (5)
Changes in PSA kinetics after DNA vaccine therapy-not so fast! (2010) (5)
Immunotherapy for biochemically recurrent prostate cancer. (2018) (5)
Time to PSA nadir and the risk of death from prostate cancer following radiation and androgen deprivation therapy. (2019) (5)
PROTEUS: A randomized, double-blind, placebo (PBO)-controlled, phase III trial of apalutamide (APA) plus androgen deprivation therapy (ADT) versus PBO plus ADT prior to radical prostatectomy (RP) in patients with localized high-risk or locally advanced prostate cancer (PC). (2019) (5)
Relationship of sipuleucel-T with time to first use of opioid analgesics (TFOA) in patients (pts) with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC) on the IMPACT trial. (2013) (5)
A dose finding clinical trial of cabozantinib (XL184) administered in combination with abiraterone acetate in metastatic castration‐resistant prostate cancer (2018) (5)
Biochemical outcome following external beam radiation therapy with or without androgen suppression therapy for patients with clinically localized prostate cancer (2000) (5)
Characterization of patients who present with de novo metastatic prostate cancer: Single-institution database analysis. (2013) (5)
Natural History of Untreated Prostate Specific Antigen Radiorecurrent Prostate Cancer in Men with Favorable Prognostic Indicators (2014) (5)
Publisher Correction: The long tail of oncogenic drivers in prostate cancer (2019) (5)
Low testosterone at first prostate‐specific antigen failure and assessment of risk of death in men with unfavorable‐risk prostate cancer treated on prospective clinical trials (2018) (5)
New and emerging treatments for advanced prostate cancer. (2011) (5)
Biopsy Gleason score and the duration of testosterone suppression among men treated with external beam radiation and 6 months of combined androgen blockade (2012) (5)
Testicular cancer. Clinical practice guidelines. (2005) (5)
Multicenter phase II study of trabectedin in patients with metastatic castration-resistant prostate cancer. (2012) (4)
Phase I study of the novel, oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK): Evaluating the pharmacokinetic effect of a high-fat meal in patients with hormone-refractory prostate cancer (HRPC). (2004) (4)
[Metastatic prostate carcinoma]. (2001) (4)
The radical prostatectomy series: apples are not oranges. (1994) (4)
Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer--Reply. (2016) (4)
7002 ORAL Time to Disease-related Pain After Sipuleucel-T in Asymptomatic Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC): Results From 3 Randomized Phase III Trials (2011) (4)
Reply to clinical predictors of survival in men with castration‐resistant prostate cancer (2013) (4)
The impact of comorbidity and PSA doubling time on the risk of death in men experiencing PSA failure following radiation therapy with or with androgen deprivation therapy for unfavorable-risk prostate cancer (2017) (4)
The ingredients for prostate cancer nomograms: the addition of biomarkers sets the table for future recipes. (2003) (4)
NCCN practice guidelines for kidney cancer (1998) (4)
Prognostic and therapeutic significance of COP9 signalosome subunit CSN5 in prostate cancer (2021) (4)
Androgen Receptor Polymorphisms and Prostate Cancer Risk (2001) (4)
244 Prostate Specific Membrane Antigen Antibody Drug Conjugate (PSMA ADC): a Phase 1 Trial in Castration-Resistant Metastatic Prostate Cancer (mCRPC) (2012) (4)
Association of somatic ERCC2 mutations with cisplatin sensitivity in muscle-invasive urothelial carcinoma. (2014) (4)
Prognostic Factors in Localized Prostate Cancer (2003) (4)
Dynamic expression of SNAI2 in prostate cancer predicts tumor progression and drug sensitivity (2021) (3)
Cancer and Leukemia Group B trials for advanced prostate cancer. (1996) (3)
Interim safety and efficacy results from a phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma (2004) (3)
Maternal Antidepressant Use and Persistent Pulmonary Hypertension of the Newborn (2017) (3)
Cells Is Polycomb-Independent EZH 2 Oncogenic Activity in Castration-Resistant Prostate Cancer (2013) (3)
PROSTATE‐SPECIFIC ANTIGEN SCREENING FOR PROSTATE CANCER: A DECISION‐ANALYTICAL PERSPECTIVE (2007) (3)
Identification of a novel urothelial carcinoma (UC) biomarker of lethality. (2011) (3)
Evaluation of the SF-36 measures of health related quality of life (HRQoL) in prostate cancer: 12 (1994) (3)
ATAAA repeat upstream of glutathione S-transferase P1 and prostate cancer risk. (2002) (3)
7002 Further analysis of a Phase II randomized controlled trial (RCT) of a poxviral-based PSA targeted immunotherapy in metastatic castration-resistant prostate cancer (mCRPC) (2009) (3)
PD27-04 SIPULEUCEL-T-INDUCED ANTIGEN SPREAD: IMMUNE RESPONSE TO PROSTATE-SPECIFIC ANTIGEN CORRELATES WITH IMPROVED OVERALL SURVIVAL (2014) (3)
806POutcomes of prechemotherapy (pCRx) abiraterone acetate (AA) or enzalutamide (E) for metastatic castration-resistant prostate cancer (mCRPC) after ADT + Docetaxel (D) or ADT alone for metastatic hormone sensitive prostate cancer (mHSPC) in a multi-institution hospital-based registry (2017) (3)
204: Low-Risk Prostate Cancer: Contemporary Trends (2007) (3)
Defining the optimal approach to the patient with postradiation prostate‐specific antigen recurrence using outcome data from a prospective randomized trial (2013) (3)
Clinical Progression to Castration-Recurrent Prostate Cancer (2009) (3)
First-in-human phase I trial of prostate-specific membrane antigen antibody drug conjugate (PSMA ADC) in taxane-refractory prostate cancer. (2010) (3)
Safety profile of recombinant poxviral TRICOM vaccines. (2013) (3)
Health-related quality of life following treatment for early stage prostate cancer (Meeting abstract).: 11 (1994) (3)
Median time to progression in chemotherapy (chemo)-naive patients with castration-resistant prostate cancer (CRPC) treated with abiraterone acetate and low-dose prednisone (Pred). (2010) (3)
Chemotherapy for metastatic bladder cancer. (1992) (3)
Prostate-specific membrane antigen antibody drug conjugate (PSMA ADC): A phase I trial in men with prostate cancer previously treated with taxane. (2012) (3)
Fraction genome altered (FGA) to regulate both cell autonomous and non-cell autonomous functions in prostate cancer and its effect on prostate cancer aggressiveness. (2020) (3)
Early Versus Delayed Initiation of Salvage Androgen Deprivation Therapy and Risk of Prostate Cancer-Specific Mortality. (2018) (3)
Regular aspirin use and gene expression profiles in prostate cancer patients (2018) (3)
Histologic demonstration of intradermal spirochetes in a patient with Lyme disease. (1984) (3)
IRONMAN: The international registry for men with advanced prostate cancer. (2022) (3)
Abstract 3152: CanSeq: prospective clinical whole-exome sequencing of FFPE tumor samples. (2013) (3)
Debrisoquine Hydroxylase ( CYP 2 D 6 ) and Prostate Cancer (2005) (3)
Phase II trial of RAD001 (R) and bicalutamide (B) for castration-resistant prostrate cancer (CPRC). (2010) (3)
Polycomb-independent activity of EZH2 in castration resistant prostate cancer (2013) (3)
Germline CAG repeat length of the androgen receptor and time to progression in patients with prostate cancer treated with androgen deprivation therapy (2011) (3)
Docetaxel plus carboplatin (DC) may have significant activity in hormone refractory prostate cancer (HRPC) patients who have progressed after prior docetaxel-based chemotherapy. (2004) (3)
MP73-12 UNSUSPECTED METASTASES FOUND DURING SCREENING FOR A TRIAL OF PATIENTS WITH NON-METASTATIC CASTRATION RESISTANT PROSTATE CANCER (2015) (3)
Genitourinary tumors, prostate (2012) (3)
Retroperitoneal lymphocele formation after selective laparoscopic retroperitoneal lymph node sampling. (1994) (3)
Scatter factor/hepatocyte growth factor as a prognostic indicator in metastatic prostate cancer: A plasma study in CALGB 9480. (2004) (3)
HSD3B1 genotype and response to androgen deprivation therapy for biochemical recurrence after radiotherapy for localized prostate cancer. (2017) (3)
Leukemia Group B Study Hormone-refractory Prostate Cancer Patients : A Cancer and Growth Factor Urine Levels as Predictors of Outcome in Vascular Endothelial Growth Factor and Basic Fibroblast (2001) (3)
Simultaneous and Exact Interval Estimates for the Contrast of Two Groups Based on an Extremely High Dimensional Response Variable: Application to Mass Spec Data Analysis (2005) (3)
Next-generation sequencing (NGS) of tissue and cell free DNA (cfDNA) to identify somatic and germline alterations in advanced prostate cancer. (2017) (2)
PROTEUS: A randomized, double-blind, placebo (PBO)-controlled, phase 3 trial of apalutamide (APA) plus androgen deprivation therapy (ADT) versus PBO plus ADT prior to radical prostatectomy (RP) in patients (pts) with localized or locally advanced high-risk prostate cancer (PC). (2022) (2)
Vascular Endothelial Growth Factor and Basic Fibroblast Growth Factor Urine Levels as Predictors of Outcome in Hormone-refractory Prostate Cancer Patients : A Cancer and Leukemia Group B Study 1 (2001) (2)
Attempts at gene therapy in beta-thalassemic mice. (1985) (2)
Advances in Brief The V 89 L Polymorphism in the 5 a-Reductase Type 2 Gene and Risk of Prostate Cancer 1 (1999) (2)
The Impact of Genetic Variants in the Double-Stranded DNA Break Repair Pathway on Cancer Control in Men Treated with Radiation for Prostate Cancer (2011) (2)
Use of adrenal androgen levels to predict response to ketoconazole in patients with androgen independent prostate cancer: Results from CALGB 9583. (2004) (2)
Potential applications of gene therapy (1989) (2)
Neoadjuvant and adjuvant chemotherapy for invasive bladder cancer. (1995) (2)
Docetaxel plus carboplatin (DC) may have significant activity in hormone refractory prostate cancer (HRPC) patients who have progressed after prior docetaxel-based chemotherapy (2004) (2)
PTEN Polymorphism ( IVS 4 ) Is Not Associated with Risk of Prostate Cancer (2001) (2)
Do genetic polymorphisms predict risk of recurrence in patients with localized renal cell carcinoma? Results from a cohort study. (2011) (2)
681P Clinical and immune responses to immunotherapy in biochemically recurrent (non-metastatic castration sensitive) prostate cancer (BCRpc) (2020) (2)
Abstract 993: Whole exome sequencing of CTCs as a window into metastatic cancer (2014) (2)
Association between genetic polymorphisms in SLCO1B3 gene and response to ketoconazole (K) in men with castration-resistant prostate cancer (CRPC). (2010) (2)
Prior therapy and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC) in a hospital-based database. (2017) (2)
A Prospective Study of Aspirin Use and Prostate Cancer Risk by TMPRSS2:ERG Status (2018) (2)
Effect of prior abiraterone (ABI) or enzalutamide (ENZ) on sipuleucel-T (sip-T) manufacture in PROCEED patients (pts). (2014) (2)
Screening for prostate cancer. (2009) (2)
Analysis of the correlation between endorectal MRI response to neoadjuvant chemotherapy and biochemical recurrence in patients with high-risk localized prostate cancer (2013) (2)
Impact of time to testosterone rebound and comorbidity on the risk of cause‐specific mortality in men with unfavorable‐risk prostate cancer (2018) (2)
Fourth International Conference on Innovations and Challenges in Prostate Cancer: Prevention, Detection and Treatment. (2004) (2)
The impact of statin use on abiraterone acetate (AA) treatment duration in patients with castration-resistant prostate cancer (CRPC). (2016) (2)
Prostate cancer 2012: where do we stand and where are we heading? (2012) (2)
Clinical annotations for prostate cancer research: Defining data elements, creating a reproducible analytical pipeline, and assessing data quality (2021) (2)
Prospect: A randomized, double-blind, phase III efficacy trial of PROSTVAC. (2012) (2)
Cerebrovascular event (CVE) outcome and overall survival (OS) in patients (pts) treated with sipuleucel-T (sip-T) for metastatic castration-resistant prostate cancer (mCRPC): results from the PROCEED registry. (2018) (2)
Prevention of prostate cancer with finasteride. (2003) (2)
Bladder cancer. (1990) (2)
The impact of PIK3R1 mutations and insulin-PI3K-glycolytic pathway regulation in prostate cancer. (2022) (2)
The effect of abiraterone acetate treatment on CREB and the development of abiraterone acetate resistance in prostate cancer cells. (2020) (2)
Reply to M. Kumar et al (2010) (2)
Restoration of tumor suppression in vivo by systemic delivery of chemically-modified PTEN mRNA nanoparticles. (2017) (2)
Manganese superoxide dismutase (MnSOD) polymorphism, prediagnostic plasma antioxidants and prostate cancer risk. (2004) (2)
Defining the Optimal Approach to the Patient With Postradiation Prostate-Specific Antigen Recurrence Using Outcome Data From a Prospective Randomized Trial (2013) (2)
Prognostic significance of plasma chromogranin A levels in hormone-refractory prostate cancer patients treated on Cancer and Leukemia Group B (CALGB) 9480. (2004) (2)
Retroviral Vector‐mediated Gene Transfer and Expression in Nonhuman Primates Following Autologous Bone Marrow Transplantation a (1987) (2)
Novel genomic signature predictive of response to immune checkpoint blockade: A pan-cancer analysis from project Genomics Evidence Neo-plasia Information Exchange (GENIE). (2021) (1)
Genetic variants of the organic anion transporter SLCO2B1 as pharmacogenomic determinants of response to androgen deprivation therapy (ADT) for prostate cancer. (2015) (1)
Paradoxical significance of endorectal MRI (erMRI) response to neoadjuvant chemotherapy in patients with high-risk localized prostate cancer (HRLPC). (2013) (1)
The long tail of oncogenic drivers in prostate cancer (2018) (1)
Gene transfer into animals by retroviral vectors. (1986) (1)
Patterns of self-reported care in a cohort of prostate cancer survivors: Implications for risk-stratified care. (2020) (1)
Imaging yield from 133 consecutive patients with prostate cancer and low trigger PSA from a single institution. (2016) (1)
Abstract A91: Obesity and the TMPRSS2:ERG translocation in prostate cancer (2008) (1)
Abstract 2674: High fat diet accelerates MYC-driven prostate cancer through metabolic and epigenomic rewiring (2016) (1)
Peroxisome proliferator-activated receptor gamma (PPARG) gene amplifications in urothelial carcinoma (UC). (2013) (1)
Impact of new systemic therapies on overall survival (OS) of patients (pts) with metastatic castration resistant prostate cancer (mCRPC) in a hospital-based registry. (2018) (1)
Tumor protein expression of the DNA repair gene BRCA1 and lethal prostate cancer. (2020) (1)
Use of elevated insulin-like growth factor binding protein-1 (IGFBP-1) to predict outcomes in men with metastatic prostate cancer treated with androgen-deprivation therapy (ADT). (2012) (1)
2239 : The Influence of Androgen Suppression Therapy for Prostate Cancer on the Frequency and Timing of a Fatal Myocardial Infarction (2006) (1)
Renal cell carcinoma (2017) (1)
Does androgen deprivation therapy in men with prostate cancer increase cardiovascular morbidity? (2008) (1)
Null Results in Brief Association between the Met326Ile Polymorphism of the p85 Regulatory Subunit of Phosphatidylinositol 3-Kinase and Prostate Cancer Risk: A Prospective Study 1 (2003) (1)
American Urological Association ( AUA ) Guideline EARLY DETECTION OF PROSTATE CANCER : AUA GUIDELINE (2018) (1)
Salvage chemotherapy for testis cancer (1991) (1)
Reply to G. Francolini et al. (2021) (1)
Mifepristone (RU-486) in androgen independent prostate cancer. (2006) (1)
A phase I study of estramustine, weekly docetaxel and carboplatin (EDC) chemotherapy in patients with hormone refractory prostate cancer (HRPC). (2004) (1)
Prognostic indicators in hormone refractory prostate cancer : Hormone refractory prostate cancer (1999) (1)
An investigator-initiated phase I study of crizotinib in combination with enzalutamide in metastatic castration-resistant prostate cancer (mCRPC) before or after progression on docetaxel. (2016) (1)
Extent, impact, and mitigation of batch effects in tumor biomarker studies using tissue microarrays (2021) (1)
Genomic alterations in upper tract urothelial carcinoma (UTUC) versus urothelial carcinoma of the bladder (UBC). (2016) (1)
Response to low-dose ketoconazole and subsequent dose escalation to high-dose ketoconazole in patients with androgen-independent prostate cancer. (2006) (1)
Phase II Trial of the Antiestrogen Toremifene for Androgen‐Independent Prostate Cancer (1999) (1)
708: A Phase Ib study of BKM120 combined with abiraterone acetate for castrate-resistant, metastatic prostate cancer (2014) (1)
Genomic characterization of metastatic urothelial carcinoma. (2013) (1)
Family history of prostate cancer and the incidence of ERG‐ and phosphatase and tensin homolog‐defined prostate cancer (2019) (1)
Prostate‐specific antigen nadir and testosterone level at prostate‐specific antigen failure following radiation and androgen suppression therapy for unfavorable‐risk prostate cancer and the risk of all‐cause and prostate cancer–specific mortality (2021) (1)
Low rate of clinician-scored gynecomastia induced by 6 months of combined androgen blockade in a randomized trial: Implications for prophylactic breast irradiation. (2012) (1)
Polycomb-independent activity of EZH2 in castration resistant prostate cancer (2013) (1)
Effects of electroacupuncture and auricular acupuncture for chronic pain in cancer survivors: The PEACE randomized controlled trial. (2020) (1)
First look at patient reported outcomes from IRONMAN, the international registry of men with advanced prostate cancer. (2022) (1)
The long tail of significantly mutated genes in prostate cancer. (2017) (1)
PI3KCA mutations in advanced urothelial carcinoma: A potential therapeutic target? (2012) (1)
Association of inherited genetic variation with clinical outcome in patients with advanced renal cell carcinoma treated with mTOR inhibition. (2012) (1)
Magnetic resonance imaging and spectroscopic imaging of prostate cancer. Discussion (2003) (1)
The CAG repeat within the androgen receptor gene and benign prostatic hyperplasia. (1999) (1)
Results of a phase II trial of docetaxel (DOC), bevacizumab (BEV), and androgen deprivation therapy (ADT) for biochemical relapse (BCR) after definitive local therapy for prostate cancer (PC). (2014) (1)
Researchers The NCCN Prostate Cancer Clinical Practice Guidelines in OncologyTM (2010) (1)
A non-canonical EZH2 function sensitizes solid tumors to genotoxic stress (2020) (1)
BRCA2-RB1 co-loss and ADT resistance in aggressive prostate cancer. (2018) (1)
NCCN Prostate Cancer , Version 2 . 2014 Clinical Practice Guidelines in Oncology (2014) (1)
Increased MYBL2 expression in aggressive hormone‐sensitive prostate cancer (2022) (1)
Use of elevated baseline IL-8, CCL-2, and TNFα to predict for shorter overall survival (OS) in men with metastatic prostate cancer initiating androgen-deprivation therapy (ADT). (2012) (1)
p53 Protein Expression Status and Recurrence in Men Treated With Radiation Therapy and Androgen Suppression Therapy for Higher Risk Prostate Cancer: A Prospective Phase II Cancer and Leukemia Group B Study (2007) (1)
Effect of HOXB13 and FOXA1 on the AR cistrome during prostate tumorigenesis in primary human tissue. (2014) (1)
Association of SLCO transport genes with intraprostatic abiraterone (ABI) levels and pathologic outcomes in men with high-risk localized prostate cancer (PCa). (2015) (1)
Abstract 2542: Sipuleucel-T-induced immune response against secondary cancer antigens is associated with improved overall survival (2014) (1)
Impact of symptomatic skeletal events on healthcare resource utilization, health-related quality of life and pain among patients with castration-resistant prostate cancer and bone metastases. (2016) (1)
Reverse transcriptase polymerase chain reaction for prostate-specific antigen (RT-PCR PSA) responses may predict time to progression (TTP) in hormone refractory prostate cancer (HRPC) patients treated with chemotherapy (2005) (1)
The impact of the expression of the transcription factor MYBL2 on outcomes of patients with localized and advanced prostate cancer. (2020) (1)
Genome-wide association study (GWAS) of response to androgen deprivation therapy (ADT) and survival in metastatic prostate cancer (PCa). (2016) (1)
Abstract 4017: Dissecting the clonal hierarchy of cancer-driving genomic lesions. (2013) (1)
Response to docetaxel (D)/carboplatin (C)-based chemotherapy as first- and second-line therapy in patients with metastatic hormone-refractory prostate cancer (HRPC) (2007) (1)
Phase II study of thalidomide and celecoxib in androgen independent prostate cancer (AIPC) (2005) (1)
Kidney cancer. Clinical practice guidelines. (2005) (1)
Management of Localized Prostate Cancer (2003) (1)
Pharmacokinetic (PK) analysis of concurrent administration of enzalutamide (enza) and crizotinib (crizo) in patients with metastatic castration resistant prostate cancer (CRPC). (2018) (1)
Prostate specific antigen doubling time (PSA-DT) and velocity (PSA-V) provide independent prognostic information in androgen independent prostate cancer (AIPC) patients receiving chemotherapy. (2006) (1)
The effect of acupuncture versus cognitive behavior therapy on insomnia in cancer survivors: A randomized clinical trial. (2018) (1)
Elevated plasma TIMP-1 levels predict reduced survival in metastatic hormone-refractory prostate cancer patients (2007) (1)
Abstract 2534: A comparative analysis of fraction genome altered vs tumor mutational count in prostate cancer (2019) (1)
The impact of anemia on psa outcome following radiation and androgen suppression therapy in patients with high-risk prostate cancer (2001) (1)
Association between the Met 326 Ile Polymorphism of the p 85 Regulatory Subunit of Phosphatidylinositol 3-Kinase and Prostate Cancer Risk : A Prospective Study 1 (2003) (1)
Signs and Symptoms (2018) (0)
Low testosterone at first PSA failure and assessment of the risk of death in men with unfavorable-risk prostate cancer treated on prospective clinical trials. (2018) (0)
Abstract 1650: Non-invasive imaging tool to predict BRCA2 silencing in the context of prostate cancer (2020) (0)
Reply form Authors re: Bertrand Tombal. Continuous Improvement Versus Innovation: The Case for Sipuleucel-T. Eur Urol 2012;61:648–9 (2012) (0)
Regular aspirin use and gene expression profiles in prostate cancer patients (2018) (0)
Outcomes of prechemotherapy (pCHT) abiraterone (AA) or enzalutamide (E) for metastatic castration-resistant prostate cancer (mCRPC) after androgen deprivation therapy (ADT) + docetaxel (D) or ADT alone for metastatic hormone sensitive prostate cancer (mHSPC) in a hospital-based registry. (2017) (0)
Abstract A10: High-fat diet enhances MYC-driven prostate cancer through epigenomic and metabolomic rewiring (2016) (0)
Phase 1 study with expansion cohorts of cabozantinib (C) + abiraterone (A) in metastatic castration resistant prostate cancer (mCRPC): Investigator-sponsored study. (2015) (0)
Abstract 957: Towards precision functional genomics via next-generation functional mapping of cancer variants (2015) (0)
Prognostic M odel f or P redicting S urvival i n M en W ith Hormone-Refracto ry M etastatic P rostate C ancer (2003) (0)
The Cooperative Group Bulletin Board Cooperative Group Tissue Banks As Research Resources : The Cancer and Leukemia Group B Tissue Repositories 1 (2002) (0)
Abstract 2498: Amine and lipid metabolites are enriched in advanced prostate cancer (2017) (0)
Experience with sipuleucel-T in metastatic castration-resistant prostate cancer (mCRPC) with visceral spread from PROCEED. (2019) (0)
Abstract LB-275: Targeting poor-prognosis subtypes of prostate cancer by inhibition of DNA repair gene ribonucleotide reductase small subunit M2 (2018) (0)
Utility of prostate specific antigen doubling time (PSA-DT) at the start of androgen independent prostate cancer (AIPC) and immediately before chemotherapy in predicting efficacy of taxane chemotherapy. (2006) (0)
Genomic Evaluation and Management of Prostate Cancer (2010) (0)
Genitourinary malignancies. (1999) (0)
A validated whole-blood RNA transcript-based prognostic model that predicts survival in men with castration-resistant prostate cancer. (2012) (0)
Sipuleucel-T (2019) (0)
Duration of the anti-androgen in men undergoing 6 months of an LHRH agonist and radiation therapy for unfavorable-risk prostate cancer and the risk of death (2016) (0)
TREATMENT OF PROSTATE CANCER — HORMONAL THERAPY (2011) (0)
Abstract 6219: Combined inhibition of androgen signaling and apoptosis pathways in hormone sensitive prostate cancer (2020) (0)
Elevated plasma TIMP-1 and survival in metastatic castration-resistant prostate cancer patients (2008) (0)
Resource Integrative Clinical Genomics of Advanced Prostate Cancer (2016) (0)
Utilizing P redictions o f E arly P rostate-Specifi c A ntigen Failure t o O ptimize P atient S election f or A djuvant Systemic T herapy T rials (2000) (0)
MP50-20 IMPACT OF ABIRATERONE ACETATE IN PROSTATE SPECIFIC ANTIGEN TRIAL UPDATE: EFFECT OF ABIRATERONE ACETATE AND LOW DOSE PREDNISONE ON PROSTATE-SPECIFIC ANTIGEN AND RADIOGRAPHIC DISEASE PROGRESSION IN PATIENTS WITH NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (2016) (0)
Abstract 863: Circadian gene expression in metastatic sites and association with survival in metastatic castration-resistant prostate cancer (2021) (0)
The impact of prior therapy with ketoconazole (keto) on clinical outcomes after subsequent docetaxel treatment in metastatic castration-resistant prostate cancer (mCRPC) patients: Results from a randomized phase III trial (CALGB 90401). (2012) (0)
New Perspectives on Chemotherapy in Prostate Cancer (2008) (0)
DECREASED EXPRESSION OF MALE SPECIFIC HISTONE DEMETHYLASE “KDM5D” IS PROGNOSTIC FOR DEVELOPMENT OF CASTRATION‐RESISTANT PROSTATE CANCER: MP28‐14 (2017) (0)
Do more granular Gleason categorizations lead to better prognostic accuracy over time (2017) (0)
Abstract 3925: Characterization of complex chromosomal aberrations in prostate cancer from whole genome sequencing (2011) (0)
Abstract B31: Single-cell multiplex immunofluorescence of formalin-fixed, paraffin-embedded prostate cancer tissue identifies PI3K pathway activation in two prospective cohort studies (2020) (0)
Early versus delayed initiation of salvage androgen deprivation therapy and the risk of prostate cancer-specific mortality. (2018) (0)
Tissue and in Carcinoma Two Differentially Expressed Genes in Normal Human Prostate (2006) (0)
Tumor protein expression of BRCA1 and development of lethal prostate cancer. (2020) (0)
Benchmarks for Academic Oncology Faculty. (2020) (0)
Correlation between time to prostate cancer metastasis and overall survival after androgen-deprivation therapy initiation. (2015) (0)
First look at the baseline characteristics of participants in IRONMAN, the international registry for men with advanced prostate cancer. (2023) (0)
NEW ALTERNATIVES FOR THE MANAGEMENT OF PATIENTS WITH HORMONE-REFRACTORY PROSTATE CANCER (2006) (0)
Abstract LB-166: Cabozantinib (cabo) + abiraterone (abi) combination therapy in castration resistant prostate cancer (CRPC): preclinical evaluation and interim results of an investigator-sponsored phase 1 clinical study. (2013) (0)
Using molecular markers to predict outcome. Discussion (2004) (0)
Consensus Summary FOURTH INTERNATIONAL CONFERENCE ON INNOVATIONS AND CHALLENGES IN PROSTATE CANCER: PREVENTION, DETECTION AND TREATMENT (2005) (0)
A comparison of surrogate endpoints for all cause mortality in men with localized unfavorable-risk prostate cancer. (2017) (0)
Sipuleucel-T Immunotherapy for the Treatment of Castration-Resistant Prostate Cancer (2011) (0)
Use of elevated baseline IL-8, CCL-2, and TNFα to predict for shorter overall survival (OS) in men with metastatic prostate cancer initiating androgen-deprivation therapy (ADT). (2012) (0)
Application of OligonucleotideMicroarrays toAssess the Biological Effects of Neoadjuvant ImatinibMesylateTreatment for Localized Prostate Cancer (2005) (0)
Abstract A02: Expanding tumor chemical-genetic interaction map using next-generation cancer models (2017) (0)
Neuroepithelial tumor arising in a testicular teratoma with retroperitoneal metastasis. (2012) (0)
Gleason score and the risk of cause-specific and all-cause mortality following radiation with or without 6 months of androgen deprivation therapy for men with unfavorable-risk prostate cancer (2016) (0)
Gleason grade 5 and the risk of death from prostate cancer following radiation with or without 6 months of conventional androgen deprivation therapy. (2015) (0)
Abstract CT418: A Phase Ib study of BKM120 combined with abiraterone acetate for castrate-resistant, metastatic prostate cancer (2014) (0)
Ejaculation frequency and prostate cancer: A large, prospective study with 16 years of follow-up. (2013) (0)
Secondary Tumors of the Ureter (2003) (0)
A decision analytic model of prostate cancer screening using prostate-specific antigen and digital rectal exam (2007) (0)
PD59-02 IMPACT OF 5?-REDUCTASE INHIBITORS AND ?-BLOCKERS FOR BENIGN PROSTATIC HYPERPLASIA ON PROSTATE CANCER INCIDENCE AND MORTALITY (2018) (0)
Abstract 5168: Tumor metabolism as a driver of lethal prostate cancer (2015) (0)
Postrandomization analysis assessing survival following radiation therapy (RT) with or without 6 months of androgen suppression therapy (AST) for localized prostate cancer (PCa). (2016) (0)
Regulation of the tumor suppressor PLZF and prostate cancer prognosis. (2018) (0)
Aggressive prostate cancer by the loss of male specific histone demethylase ‘KDM5D’ (2018) (0)
970 PROSPECT: A RANDOMIZED, DOUBLE-BLIND, PHASE 3 EFFICACY TRIAL OF PROSTVAC-VF IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (2013) (0)
Impact of SLCO1B3 single nucleotide polymorphisms (SNPs) on outcomes in patients with castration resistant prostate cancer (CRPC) treated with docetaxel. (2018) (0)
Elevated serum activin A and survival in CRPC. (2012) (0)
Biopsy Gleason score and the duration of testosterone suppression among men treated with external beam radiation and six months of combined androgen blockade. (2011) (0)
The Impact of Androgen Deprivation Therapy on COVID-19 Illness in Men With Prostate Cancer (2022) (0)
Prostate cancer screening using PSA and DRE: A decision analytic model. (2006) (0)
Adenocarcinoma of the Bladder (2003) (0)
Comparison of Treatment Options for Localized Prostate Cancer (2003) (0)
Abstract 1450: Intratumoral CYP27A1 expression in relation to cholesterol synthesis and vitamin D signaling and its association with lethal prostate cancer (2018) (0)
Author Correction: Restoration of tumour-growth suppression in vivo via systemic nanoparticle-mediated delivery of PTEN mRNA (2018) (0)
Disease burden and outcome in metastatic hormone sensitive prostate cancer (mHSPC). (2015) (0)
DNA REPLICATION STRESS BY THE LOSS OF MALE SPECIFIC HISTONE DEMETHYLASE ‘KDM5D’ IN AGGRESSIVE PROSTATE CANCER: MP29‐01 (2018) (0)
Clinicopathologic features and clinical outcomes associated with Gleason upgrading from biopsy to radical prostatectomy. (2013) (0)
Statin use at the time of initiation of androgen deprivation therapy (ADT) and time to progression (TTP) in patients with hormone-sensitive prostate cancer. (2015) (0)
Institutional retrospective review of presurgical cisplatin-based chemotherapy (chemo) in patients with urothelial carcinoma (UC): Gemcitabine+cisplatin (GC) versus dose-dense methotrexate, vinblastine, doxorubicin, cisplatin (ddMVAC). (2015) (0)
Long non-coding RNA-mediated PTEN regulation in prostate cancer. (2015) (0)
External validation of somatic copy number alteration (SCNA) at chromosome 1q23.3 in advanced urothelial carcinoma (UC). (2012) (0)
Checkpoint kinase inhibition in prostate cancer cells resistant to poly ADP-ribose polymerase inhibitors. (2020) (0)
Quantitative gene expression at the 8q24 prostate cancer risk locus (2008) (0)
DNA copy number analysis of metastatic urothelial carcinoma with comparison to primary tumors (2015) (0)
Precision prevention of TMPRSS2:ERG prostate cancer. (2016) (0)
Squamous Cell Carcinoma (2003) (0)
Abstract 283: Combination treatment of PARP and SRC inhibitors in BRCA2 mutated prostate cancer (2019) (0)
Management of Disseminated Cancer (2003) (0)
Abstract LB-69: Novel WBC gene expression assay for prostate cancer detection. (2013) (0)
665 EFFECT OF NEOADJUVANT ABIRATERONE ACETATE PLUS LEUPROLIDE ACETATE ON PSA, PATHOLOGIC RESPONSE, AND INTRAPROSTATIC/SERUM ANDROGEN LEVELS IN LOCALIZED HIGH-RISK PROSTATE CANCER: RESULTS OF A RANDOMIZED PHASE 2 STUDY (2013) (0)
Abstract 1438: Organic anion transporter(SLCO)genotype and prostate cancer progression: Prospective cohort study and meta-analysis (2022) (0)
Age, comorbidity, and the risk of death in men with PSA failure following radiation therapy. (2013) (0)
Publisher Correction: The long tail of oncogenic drivers in prostate cancer (2019) (0)
AWARD NUMBER: W81XWH-14-1-0515 TITLE: SLCO2B1 and SLCO1B3 as New Targets for Enhancing Androgen Deprivation Therapy for Prostate Cancer. PRINCIPAL INVESTIGATOR: (2016) (0)
AWARD NUMBER: W81XWH-14-1-0515 TITLE: SLCO2B1 and SLCO1B3 as New Targets for Enhancing Androgen Deprivation Therapy for Prostate Cancer. PRINCIPAL INVESTIGATOR: (2016) (0)
Paclitaxel, E stramustine P hosphate, a nd C arboplatin i n Patients W ith A dvanced P rostate C ancer (2006) (0)
Results of a phase II trial of abiraterone acetate (AA) combined with dutasteride (DUT) for men with metastatic castration resistant prostate cancer (mCRPC). (2014) (0)
Abstract 3566: The long tail of significantly mutated genes in prostate cancer (2017) (0)
Androgen Suppression Plus Radiation Therapy for Prostate Cancer—Reply (2004) (0)
A Genetic Variation of SOD2 Does Not Determine Duration of Response to Androgen Deprivation Therapy for Prostate Cancer (2016) (0)
Sarcomas of Renal Origin (2003) (0)
Methylation-associated miR193b silencing activates master drivers of aggressive prostate cancer. (2019) (0)
Abstract LB-240: Immuno-genomic detection and prognostication of aggressive prostate cancer phenotypes by next-generation RNA sequencing (2019) (0)
Abstract 4327: Hypermethylation of miR193b reactivates master drivers of the poor prognosis prostate cancer (2019) (0)
A biochemical study of the mitochondrial proline oxidase complex in normal and hyperprolinaemic mice. (1974) (0)
Opportunities for Targeted Molecular Therapy for Prostate Cancer (2004) (0)
Wilms Tumor (Nephroblastoma) (2003) (0)
HRAS1 Proto-Oncogene Polymorphism and Prostate Cancer (2000) (0)
Restoration of tumour-growth suppression in vivo via systemic nanoparticle-mediated delivery of PTEN mRNA (2018) (0)
A phase I study of estramustine, weekly docetaxel and carboplatin (EDC) chemotherapy in patients with hormone refractory prostate cancer (HRPC) (2004) (0)
SLCO2B1 and SLCO1B3 as New Targets for Enhancing Androgen Deprivation Therapy for Prostate Cancer (2015) (0)
Identification of ALK gene alterations in urothelial carcinoma (UC). (2011) (0)
Cancer Therapy : Clinical Phase II Study of Androgen Synthesis Inhibition with Ketoconazole , Hydrocortisone , and Dutasteride in Asymptomatic Castration-Resistant Prostate Cancer (2009) (0)
Androgen R eceptor M utations i n A ndrogen-Indepen dent Prostate C ancer: C ancer a nd L eukemia G roup B S tudy 9 663 (2003) (0)
Prostate-specific membrane antigen antibody drug conjugate (PSMA ADC): A phase I trial in men with prostate cancer previously treated with taxane. (2012) (0)
Associations between single nucleotide polymorphisms (SNPs) in inflammation-related genes and quality of life after radiation therapy (RT) for prostate cancer. (2013) (0)
Abstract D084: Overall survival (OS) of African-American (AA) and Caucasian (CAU) men who received sipuleucel-T for metastatic castration-resistant prostate cancer (mCRPC)—final PROCEED analysis (2020) (0)
Abstract B024: Family history of prostate cancer and the incidence of ERG- and PTEN-defined prostate cancer (2018) (0)
Post prostatectomy outcomes of patients with high-risk prostate cancer treated with neoadjuvant androgen blockade (2017) (0)
Table 111-6, Probability of Cancer in Patients with PSA Levels between 4 and 10 ng/mL Using Different Percent-Free PSA Values (2003) (0)
Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry (2020) (0)
LAPAROSCOPIC RETROPERITONEAL LYMPH NODE DISSECTION (RPLND) FOR CLINICAL STAGE I NONSEMINOMATOUS GERM CELL TESTICULAR TUMORS (NSGCT) (1999) (0)
Appendix 2. Draft Proposal for a Harvard Vaccine Institute (0)
Innovations and challenges in prostate cancer: summary statement for the 6th Cambridge Conference. (2007) (0)
Time C ourse a nd P redictors o f S ymptoms A fter P rimary Prostate C ancer T herapy (2008) (0)
Abstract 2498: Identification and characterization of thePIK3R1-mutant subtype in PI3K-addicted prostate cancer (2021) (0)
Gleason score and the risk of cause-specific and all-cause mortality following radiation with or without 6 months of androgen deprivation therapy for men with unfavorable-risk prostate cancer (2016) (0)
Targeting checkpoint kinases in prostate cancer cells resistant to poly ADP-ribose polymerase inhibitors. (2019) (0)
Abstract 4601: Punctuated evolution of prostate cancer genomes. (2013) (0)
1314 RECURRENT MUTATIONS IN SPOP DEFINE A DISTINCT MOLECULAR CLASS OF PROSTATE CANCER (2012) (0)
Association of serum (SR) and tissue (TX) abiraterone (ABI) levels with intraprostatic steroids and pathologic outcomes in men with high-risk localized prostate cancer (PCa). (2014) (0)
Superficial Bladder Carcinoma (2020) (0)
Abstract LB-212: IMAAGEN study biomarker analysis in patients with long term response to abiraterone acetate with prednisone for non-metastatic castrate resistant prostate cancer (2018) (0)
Table 110-6, Overall 5-year Survival and Bladder Preservation: Modern Series (1997-1998) (2003) (0)
Tumor genomic mutation profiling of germ cell tumors using “Profile”. (2014) (0)
Abstract B022: Diversity of enrollment in prostate cancer clinical trials: Current status and future directions (2020) (0)
MP87-19 EFFECT OF ABIRATERONE ACETATE AND LOW DOSE PREDNISONE ON PROSTATE-SPECIFIC ANTIGEN IN PATIENTS WITH NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: THE RESULTS FROM IMPACT OF ABIRATERONE ACETATE IN PROSTATE-SPECIFIC ANTIGEN CORE STUDY (2015) (0)
UROLOGICAL ONCOLOGY: PROSTATE CANCER Autoantibody Signatures in Prostate Cancer (2006) (0)
Prostate cancer. (1993) (0)
Abstract PR07: Towards precision functional genomics via next-generation functional mapping of cancer variants (2015) (0)
Table 111-18, Secondary Hormonal Therapies for Androgen-Independent Prostate Cancer (2003) (0)
Chemotherapy for Metastatic Disease (2003) (0)
Integrative Copy Number and Mutational Analysis Improves Glioma Diagnostics (2014) (0)
Overall Survival Benefit with Sipuleucel-T by Baseline Prostate-Specific Antigen (PSA): An Exploratory Analysis from Three Phase 3 Trials (2012) (0)
Abstract 4367: Accelerating prediction of tumor vulnerabilities using next-generation cancer models (2016) (0)
Effect of a germline polymorphism in the manganese superoxide dismutase (MnSOD) gene on the association of clinically aggressive prostate cancer with plasma selenium levels (2008) (0)
Significance of targeting the antiapoptotic pathway in castration-sensitive prostate cancer. (2021) (0)
Sipuleucel-T (2020) (0)
Evaluation of an RNAseq-Based Immunogenomic Liquid Biopsy Approach in Early-Stage Prostate Cancer (2021) (0)
Abstract 3450: Resistance to P450c17 inhibitors in castration-resistant prostate cancer may result from the DHEA-S depot that remains and can be used by AKR1C3 for intratumoral androgen biosynthesis (2015) (0)
Imag Sing Agg Tong Matth Abst (2010) (0)
Somatic ERCC2 Mutations Confer Cisplatin Sensitivity in Muscle-Invasive Urothelial Cancer (2014) (0)
8 – Cancer of the Genitourinary Tract (2010) (0)
Prognostic and therapeutic significance of ribonucleotide reductase small subunit M2 in prostate cancer. (2018) (0)
Abstract B26: Accelerating prediction of tumor vulnerabilities using next-generation cancer models (2016) (0)
PP138 A whole blood RNA transcript-based model to predict biopsy Gleason score in newly diagnosed prostate cancer patients (2009) (0)
Reply to L. León et al (2010) (0)
Re-inventing the medical treatment of advanced prostate cancer (2012) (0)
Differences in Prostate Cancer Transcriptomes by Age at Diagnosis: Are Primary Tumors from Older Men Inherently Different? (2022) (0)
Concurrent deletion of BRCA2 and RB1 and aggressive prostate cancer. (2018) (0)
Abstract A10: LncRNA MIR222HG transcribed from the miR-221/222 promoter are associated with the development of castration resistant prostate cancer (2016) (0)
SHORT-TERM OUTCOMES FOLLOWING ORAL HORMONAL PROSTATE CANCER THERAPIES BY PRE-EXISTING CARDIOVASCULAR CONDITIONS: A POPULATION-BASED STUDY (2019) (0)
Abstract 174: MicroRNA signatures of castration resistant human prostate cancer (2011) (0)
Evaluation of the SF-36 measures of health related quality of life (HRQoL) in prostate cancer (Meeting abstract). (1997) (0)
Commentary (Oh/Kantoff): The Role of Cytotoxic Chemotherapy in Prostate Cancer (2006) (0)
Treatment of Metastatic Disease (2003) (0)
Transcriptional and post-transcriptional regulation of ribonucleotide reductase (RRM2) control its oncogenic role in prostate cancer progression. (2018) (0)
Abstract 4470: Aneuploidy drives lethal progression in prostate cancer (2019) (0)
Endothelin inhibition: Novel therapy for prostate cancer. Discussion (2003) (0)
Hydrocortisone W ith o r W ithout M itoxantrone i n M en W ith Hormone-Refractory P rostate C ancer: R esults o f t he C ancer and L eukemia G roup B 9 182 S tudy (1999) (0)
Characterization of isozyme alleles in two subspecies of mus musculis and their use in locating linkages of chromosomal inversions. (1971) (0)
Repeat Polymorphism and Risk of TMPRSS 2 : ERG – Positive Prostate Cancer (2014) (0)
New Approaches to Prostate Cancer Therapy (2003) (0)
Predictive Biomarkers and Personalized Medicine A Single Nucleotide Polymorphism in In fl ammatory Gene RNASEL Predicts Outcome after Radiation Therapy for Localized Prostate Cancer (2013) (0)
Provision of subspecialized expert oncology (SEO) opinions using Navya Cancer Data Model (NCDM), a technology-based platform: Prospective study to facilitate access to care. (2021) (0)
Use of elevated insulin-like growth factor binding protein-1 (IGFBP-1) to predict outcomes in men with metastatic prostate cancer treated with androgen-deprivation therapy (ADT). (2012) (0)
Association of Gleason 9-10 prostate cancer with worse outcomes compared to Gleason 8 disease. (2013) (0)
Abstract 1308:CDK12alterations define a distinct molecular subtype of prostate cancers with unique genomic and clinical characteristics (2020) (0)
Prostate-specific membrane antigen antibody-drug conjugate (PSMA ADC): A phase I trial in taxane-refractory prostate cancer. (2011) (0)
Abstract A25: Tumor metabolism as a driver of lethal prostate cancer (2016) (0)
Comorbidity, Body Mass Index, and Age and the Risk of Non-prostate Cancer-specific Mortality following a Postradiation PSA Recurrence (2009) (0)
Reply to Potential underestimation of cerebrovascular events in the PROVENGE Registry for the Observation, Collection, and Evaluation of Experience Data (2020) (0)
Association of genetic polymorphisms in ERCC1 gene with PSA response to carboplatin chemotherapy in men with metastatic castration-resistant prostate cancer (CRPC). (2010) (0)
Abstract A29: The TMPRSS2:ERG gene fusion, ERG expression and prostate cancer outcomes: A cohort study and meta-analysis (2011) (0)
Chemotherapy f or T eratoma W ith M alignant T ransformation (2003) (0)
MP21-01 MOLECULAR TUMOR PROFILING TO IDENTIFY MECHANISMS LINKING STATINS WITH LOWER RISK OF LETHAL PROSTATE CANCER (2018) (0)
Vasectomy and risk of lethal prostate cancer: A 24-year prospective study. (2013) (0)
Percent positive biopsy cores and the risk of death from prostate cancer in men with unfavorable-risk prostate cancer (2014) (0)
A phase II trial of abiraterone acetate (AA) without prednisone in castration resistant prostate cancer (CRPC). (2017) (0)
Is Change in Testosterone Levels associated with an increase in Prostate Cancer Risk? Results from the Massachusetts Male aging Study (MMAS) (2006) (0)
Prevalence and predictors of suicidal ideation in long-term prostate cancer survivors. (2013) (0)
IRONMAN: A Novel International Registry of Men With Advanced Prostate Cancer (2022) (0)
Table 111-11, Multi-Institutional Pooled Analysis of 2,758 Men with Clinically Localized Prostate Cancer Treated with Radical Prostatectomy Followed for 10 Years (2003) (0)
ANDROGEN SUPPRESSION AND RADIATION VS RADIATION FOR PROSTATE CANCER: A RANDOMIZED TRIAL AND ANALYSIS OF THE PROGNOSTIC SIGNIFICANCE OF COMORBIDITY (2008) (0)
Title Active surveillance for early-stage prostate cancer : Review of the current literature Permalink (2008) (0)
123 Time to disease-related pain (TDRP) following sipuleucel-T in asymptomatic patients with metastatic castrate-resistant prostate cancer (mCRPC): Integrated results from three randomized phase 3 trials (2012) (0)
Follow-up study of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer. (2011) (0)
Everolimus / pazopanib (E/P) benefits genomically selected patients (pts) with metastatic urothelial carcinoma (mUC) (2016) (0)
Prognostic S ignificance o f R everse T ranscriptase P olymerase Chain R eaction f or P rostate-Specifi c A ntigen i n M etastatic Prostate C ancer: A N ested S tudy W ithin C ALGB 9 583 (2003) (0)
Neoplasms of the Renal Pelvis and Ureter (2003) (0)
Genetic polymorphisms’ influence in outcome of metastatic renal cell cancer patients treated with VEGF-targeted agents. (2012) (0)
TIME TO BIOCHEMICAL RECURRENCE (BCR) IN PATIENTS WITH LOCALIZED HIGH‐RISK PROSTATE CANCER (PC) TREATED WITH NEOADJUVANT ANDROGEN BLOCKADE (NAB) PRIOR TO RADICAL PROSTATECTOMY (RP): RESULTS OF A POOLED ANALYSIS OF THREE PHASE 2 TRIALS: PD10‐02 (2017) (0)
Abstract P011: Clonal hematopoiesis and risk of lethal prostate cancer: a prospective cohort study with long-term follow-up (2023) (0)
Abstract 893: Batch effects in tumor biomarker studies using tissue microarrays: Extent, impact, and remediation (2021) (0)
Abstract 979: Bcl-2 inhibitor enhances anti-androgen therapy induced regression of castration sensitive prostate cancer (2021) (0)
Impact of new systemic therapies on overall survival of patients with metastatic castration-resistant prostate cancer in a hospital-based registry (2019) (0)
Abstract 339: Mechanisms of resistance to poly (ADP-ribose) polymerase inhibitors in prostate cancer (2019) (0)
Associations of prostate cancer risk variants with disease aggressiveness: results of the NCI-SPORE Genetics Working Group analysis of 18,343 cases (2015) (0)
Percent Positive Biopsy Cores and the Risk of Death from Prostate Cancer in Men Treated with Radiation and Androgen Deprivation Therapy (2014) (0)
Smoking history and disease outcomes in patients with malignant germ cell tumors. (2013) (0)
Medical Management of Prostate Cancer (2014) (0)
Emerging role of adjuvant hormonal therapy. Discussion (2002) (0)
PD52-06 COMPUTATIONAL IMMUNOGENOMIC MODELING OF IMMUNOEVASIVE AGGRESSIVE PROSTATE CANCER (2020) (0)
Surgical Considerations for Metastatic Disease (2003) (0)
Post-Treatment Prostate-Specific Antigen Nadir is Predictive of All-Cause Mortality: A Reanalysis of the Dana Farber Cancer Institute Radiation With or Without Androgen Deprivation Therapy Randomized Trial (2011) (0)
The role of tumor metabolism as a driver of prostate cancer progression and lethal disease: results from a nested case-control study (2016) (0)

This paper list is powered by the following services:

Other Resources About Philip Kantoff

en.wikipedia.org

What Schools Are Affiliated With Philip Kantoff?

Philip Kantoff is affiliated with the following schools:

Philip Kantoff's Academic­Influence.com Rankings

Philip Kantoff's Degrees

Why Is Philip Kantoff Influential?

Philip Kantoff's Published Works

Published Works

Other Resources About Philip Kantoff

What Schools Are Affiliated With Philip Kantoff?

Philip Kantoff's AcademicInfluence.com Rankings